<!DOCTYPE html><html lang="en" class="scroll-smooth"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>54 Targeted Therapy And Monoclonal Antibodies - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
 
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
 
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}

    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        PrepLadder / qBank / Pharmacology
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">13</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls="">
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd"></path>
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z"></path>
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>const _0x3e8868=_0x2020;(function(_0x77d39e,_0x121b71){const _0x917b1c=_0x2020,_0x2cb4aa=_0x77d39e();while(!![]){try{const _0x5b8ca3=parseInt(_0x917b1c(0x2ca))/0x1+parseInt(_0x917b1c(0x1cd))/0x2+-parseInt(_0x917b1c(0x13b))/0x3*(parseInt(_0x917b1c(0x330))/0x4)+parseInt(_0x917b1c(0x1d0))/0x5+parseInt(_0x917b1c(0x2bc))/0x6+-parseInt(_0x917b1c(0x21c))/0x7*(-parseInt(_0x917b1c(0x118))/0x8)+parseInt(_0x917b1c(0x248))/0x9*(-parseInt(_0x917b1c(0x26f))/0xa);if(_0x5b8ca3===_0x121b71)break;else _0x2cb4aa['push'](_0x2cb4aa['shift']());}catch(_0x3f6350){_0x2cb4aa['push'](_0x2cb4aa['shift']());}}}(_0x1d31,0xe761b));const _0x1a7cbf=(function(){const _0x5cdc1b=_0x2020,_0x47ca2f={'uBzmF':_0x5cdc1b(0x2d0),'BlmrG':'RZwuj','RLZzp':_0x5cdc1b(0x149),'jwZyb':_0x5cdc1b(0x121),'hhbav':_0x5cdc1b(0x1ed),'obEOq':_0x5cdc1b(0x122)};let _0x149bd5=!![];return function(_0x3bd932,_0x45ea71){const _0x185ffe=_0x5cdc1b,_0x283843={'OzIxo':_0x47ca2f[_0x185ffe(0xd4)],'hDyof':_0x47ca2f[_0x185ffe(0x30b)]},_0x3be276=_0x149bd5?function(){const _0x8b726=_0x185ffe,_0x3f17ff={'hpXEW':_0x47ca2f[_0x8b726(0x23a)],'OLvhD':_0x8b726(0x1e0),'PTtbc':function(_0x4a1ebf,_0x70eb9c){return _0x4a1ebf(_0x70eb9c);},'wCQUX':_0x8b726(0x1e6),'ZBKfC':_0x8b726(0x1f9)};if(_0x47ca2f[_0x8b726(0x17b)]===_0x47ca2f[_0x8b726(0x17b)]){if(_0x45ea71){if(_0x47ca2f[_0x8b726(0x102)]===_0x47ca2f[_0x8b726(0xd1)])_0x121f4c[_0x8b726(0x1d2)][_0x8b726(0x32d)]((_0x1cf6cf,_0x495bd9)=>{const _0xd38804=_0x8b726,_0x522542=_0x28d53c['fromCharCode'](0x41+_0x495bd9),_0x506852=_0x198163===_0x495bd9,_0x59885c=_0x3ed503[_0xd38804(0x1c7)](_0xd38804(0x198));_0x59885c[_0xd38804(0x2a7)]=_0xd38804(0x1c3)+(_0x506852?_0x3f17ff[_0xd38804(0x1f1)]:'')+_0xd38804(0x1b3)+_0x495bd9+'\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-letter\x22>'+_0x522542+_0xd38804(0x152)+(_0x1cf6cf[_0xd38804(0x1a2)]||_0x3f17ff[_0xd38804(0x26b)]+(_0x495bd9+0x1))+'</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</button>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20',_0x1a0462[_0xd38804(0x277)](_0x59885c);}),_0x2fbdde[_0x8b726(0x33f)](_0x3f17ff[_0x8b726(0x1c9)],function(_0x8b978e){const _0x13b2b0=_0x8b726,_0x2b53f2=_0x8b978e[_0x13b2b0(0x213)][_0x13b2b0(0x120)](_0x13b2b0(0x21b));if(_0x2b53f2){const _0x1adcbf=_0x3f17ff[_0x13b2b0(0x20a)](_0x3913c0,_0x2b53f2['getAttribute'](_0x3f17ff['wCQUX']));_0x3f17ff[_0x13b2b0(0x20a)](_0x5a3ea8,_0x1adcbf);}});else{const _0x52e05b=_0x45ea71[_0x8b726(0xd7)](_0x3bd932,arguments);return _0x45ea71=null,_0x52e05b;}}}else{if(_0x2ae781[_0x8b726(0x285)]!==null)_0x3486e4=_0x283843[_0x8b726(0x366)];else _0x14c6f8=_0x283843['hDyof'];}}:function(){};return _0x149bd5=![],_0x3be276;};}()),_0x5e9a74=_0x1a7cbf(this,function(){const _0x39e15e=_0x2020,_0xc6143e={'lwQYk':'(((.+)+)+)+$'};return _0x5e9a74[_0x39e15e(0x132)]()[_0x39e15e(0x11e)](_0xc6143e['lwQYk'])[_0x39e15e(0x132)]()[_0x39e15e(0x101)](_0x5e9a74)[_0x39e15e(0x11e)](_0xc6143e[_0x39e15e(0x1fa)]);});_0x5e9a74();function _0x1d31(){const _0x269bcf=['zmPqh','yPLYD','fhyMQ','eaWBK','NaMXL','GnIBg','MQwfE','click','lwQYk','https://image.prepladder.com/content/0C8jhujzXaGTU5Jv4mnG1749201687.mp3','nzRhj','feiaC','open','quizHierarchy','epGXy','KdSiP','MMsIC','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish:</p><audio\x20src=\x22','-600\x20text-white\x22>','fRvEa','TeZZp','zppMb','referrer','IBKMr','PTtbc','Hodgkin\x27s\x20Lymphoma','nav-btn-marked-review','HDbdT','1-D,\x202-C,\x203-B,\x204-A','\x22\x20data-src=\x22','push','round','xjtzq','target','UJMae','padStart','KnuqW','FlGsf','EWOIe','dOfFh','explanation_video','.option-button','901187Uadtzk','yoCts','kLiHz','gosiM','eCqYO','uEoGl','RiNQz','MkmYV','HNPor','bookmarked','status','mztoT','WTPHf','kpFXf','https://image.prepladder.com/content/ITZAdGwJCILEaPyNOkak1749203740.mp3','FGWhj','JRHMK','qpNyB','https://image.prepladder.com/content/lWKK6hhPg6yCL2JANa4U1736435838.png','nfEtL','<p><strong>Correct\x20Answer:\x20C)\x20Trastuzumab</strong></p>\x0a\x0a<p><strong>Explanation:\x20</strong></p>\x0a\x0a<ul>\x0a\x09<li><strong>Trastuzumab\x20(Option\x20C)\x20</strong>is\x20a\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22b2b82438d6169277719287eb450079\x22>monoclonal</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229d7a12cab116927771811a0079086d\x22>antibody</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22e4865847fa169277720044d7b530b0\x22>targeting</span>\x20the\x20HER2\x20protein,\x20which\x20is\x20overexpressed\x20in\x20HER2-positive\x20breast\x20cancers.\x20This\x20patient\x20has\x20HER2\x20+ve,\x20ER\x20-ve\x20stage\x20II\x20breast\x20cancer.</li>\x0a\x09<li>It\x20binds\x20to\x20the\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22ba366417791692777187229d34e597\x22>extracellular</span>\x20domain\x20IV\x20of\x20HER2,\x20reduces\x20HER2\x20signaling,\x20and\x20can\x20induce\x20antibody-dependent,\x20immune\x20cell-mediated\x20cytotoxicity,\x20inhibiting\x20cancer\x20cell\x20proliferation.</li>\x0a\x09<li>It\x20is\x20specifically\x20used\x20to\x20treat\x20HER2-positive\x20breast\x20cancer,\x20both\x20in\x20early-stage\x20and\x20metastatic\x20settings.</li>\x0a</ul>\x0a\x0a<p><strong>Tamoxifen\x20(Option\x20A):</strong></p>\x0a\x0a<ul>\x0a\x09<li>A\x20selective\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22a58dd68b011692777187eb72633aac\x22>estrogen</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229e4959f6f316927771978bb152d440\x22>receptor</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22a4dd3586e816927771927d01e3fe29\x22>modulator</span>\x20(SERM),\x20binds\x20to\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22a58dd68b011692777187eb72633aac\x22>estrogen</span>\x20receptors\x20on\x20breast\x20cancer\x20cells,\x20thereby\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229dc12b322016927771830dff673eeb\x22>blocking</span>\x20the\x20effects\x20of\x20estrogen,\x20which\x20can\x20promote\x20the\x20growth\x20of\x20breast\x20cancer\x20cells.</li>\x0a\x09<li>It\x20is\x20primarily\x20used\x20for\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22a58dd68b011692777187eb72633aac\x22>estrogen</span>\x20receptor-positive\x20(ER+)\x20breast\x20cancer.</li>\x0a</ul>\x0a\x0a<p><strong>Cetuximab\x20(Option\x20B)</strong>:</p>\x0a\x0a<ul>\x0a\x09<li>It\x20is\x20a\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22b2b82438d6169277719287eb450079\x22>monoclonal</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229d7a12cab116927771811a0079086d\x22>antibody</span>\x20that\x20targets\x20the\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22616d85c57416927771875ef23f6751\x22>epidermal</span>\x20growth\x20factor\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229e4959f6f316927771978bb152d440\x22>receptor</span>\x20(EGFR)\x20and\x20thus\x20prevents\x20cell\x20proliferation.</li>\x0a\x09<li>It\x20treats\x20certain\x20types\x20of\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22f04bf2125316927771847bfe139191\x22>colorectal</span>\x20and\x20head\x20and\x20neck\x20cancers\x20that\x20overexpress\x20EGFR\x20rather\x20than\x20HER2.</li>\x0a</ul>\x0a\x0a<p><strong>Bevacizumab\x20(Option\x20D):</strong></p>\x0a\x0a<ul>\x0a\x09<li>It\x20is\x20a\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22b2b82438d6169277719287eb450079\x22>monoclonal</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229d7a12cab116927771811a0079086d\x22>antibody</span>\x20that\x20targets\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22526ede3fee169277720184378acc5e\x22>vascular</span>\x20endothelial\x20growth\x20factor\x20(VEGF),\x20inhibiting\x20angiogenesis.</li>\x0a\x09<li>It\x20is\x20used\x20for\x20metastatic\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22f04bf2125316927771847bfe139191\x22>colorectal</span>\x20cancer,\x20non-small\x20cell\x20lung\x20cancer,\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22b9356afdba16927771979d068c6587\x22>renal</span>\x20cell\x20carcinoma,\x20and\x20glioblastoma.\x20It\x20is\x20not\x20usually\x20associated\x20with\x20the\x20treatment\x20of\x20HER2\x20+ve\x20breast\x20cancer.</li>\x0a</ul>\x0a\x0a<p><strong>Important\x20MABs\x20in\x20tumours:</strong></p>\x0a\x0a<p><img\x20alt=\x22\x22\x20data-author=\x22\x22\x20data-hash=\x22\x22\x20data-license=\x22\x22\x20data-source=\x22\x22\x20data-tags=\x22\x22\x20height=\x221824\x22\x20src=\x22https://image.prepladder.com/content/KI5ffGfpZT4iiU50IllV1736435764.png\x22\x20width=\x221999\x22\x20/></p>','pPJmA','LBYvM','correctAnswers','TaxXC','totalAttempted','FsfTd','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English:</p><audio\x20src=\x22','dataset','csdZU','uBzmF','PnUrm','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','\x20-\x20Brain\x20And\x20Scalpel','lSXwC','incomplete','ACiie','<p><strong>Correct\x20Answer:\x20D)\x20Hodgkin\x27s\x20Lymphoma</strong></p>\x0a\x0a<p><strong>Explanation:</strong></p>\x0a\x0a<ul>\x0a\x09<li><strong>Bruton’s\x20Tyrosine\x20Kinase\x20(BTK)\x20inhibitors</strong>\x20such\x20as\x20<strong>Ibrutinib</strong>,\x20<strong>Acalabrutinib</strong>,\x20and\x20<strong>Zanubrutinib</strong>\x20are\x20highly\x20effective\x20in\x20<strong>B-cell\x20malignancies</strong>\x20where\x20BCR\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22f9016f36fd1692777198b0fd5e9c6d\x22>signaling</span>\x20plays\x20a\x20central\x20role.<br\x20/>\x0a\x09\u00a0</li>\x0a\x09<li><strong>Hodgkin\x27s\x20lymphoma</strong>,\x20however,\x20is\x20<strong>not\x20a\x20B-cell\x20receptor–driven\x20malignancy</strong>\x20and\x20thus\x20<strong>not\x20commonly\x20treated</strong>\x20with\x20BTK\x20inhibitors.<br\x20/>\x0a\x09\u00a0</li>\x0a\x09<li>Standard\x20treatment\x20for\x20Hodgkin’s\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x225a31d184f21692777191a2e457d646\x22>lymphoma</span>\x20includes\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x228602c4b260169277718439bb122cb0\x22>chemotherapy</span>\x20(e.g.,\x20ABVD\x20regimen)\x20and\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x222c003a40ea1692777189ec17568ab1\x22>immunotherapy</span>\x20(e.g.,\x20anti-CD30\x20antibodies\x20like\x20Brentuximab\x20vedotin),\x20<strong>not\x20BTK\x20inhibitors</strong>.<br\x20/>\x0a\x09\u00a0</li>\x0a</ul>\x0a\x0a<p><strong>BTK\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22b5fb56a28b1692777190396ae8b625\x22>Inhibitor</span>\x20Use\x20in\x20Hematologic\x20Malignancies</strong><br\x20/>\x0a\u00a0</p>\x0a\x0a<table\x20cellspacing=\x220\x22\x20style=\x22border-collapse:collapse;\x20width:624px\x22>\x0a\x09<tbody>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Condition</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>BTK\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22b5fb56a28b1692777190396ae8b625\x22>Inhibitor</span>\x20Use</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Comments</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Mantle\x20Cell\x20Lymphoma</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Yes</strong>\x20(e.g.,\x20Ibrutinib)</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Approved\x20indication</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Marginal\x20Zone\x20Lymphoma</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Yes</strong>\x20(e.g.,\x20Zanubrutinib)</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Used\x20especially\x20in\x20relapsed/refractory\x20settings</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Chronic\x20Lymphocytic\x20Leukemia</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Yes</strong>\x20(Ibrutinib,\x20Acalabrutinib)</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>First-line\x20and\x20relapsed\x20settings</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Hodgkin\x27s\x20Lymphoma</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>No</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Not\x20a\x20BTK-driven\x20disease;\x20treated\x20with\x20chemotherapy/immunotherapy</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09</tbody>\x0a</table>\x0a\x0a<p><br\x20/>\x0a\u00a0</p>\x0a\x0a<p><strong>Mantle\x20Cell\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x225a31d184f21692777191a2e457d646\x22>Lymphoma</span>\x20(Option\x20A):</strong>\x20Incorrect.\x20BTK\x20inhibitors\x20are\x20approved\x20and\x20effective.<br\x20/>\x0a\u00a0</p>\x0a\x0a<p><strong>Marginal\x20Zone\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x225a31d184f21692777191a2e457d646\x22>Lymphoma</span>\x20(Option\x20B):</strong>\x20Incorrect.\x20BTK\x20inhibitors\x20like\x20Zanubrutinib\x20are\x20used\x20here.<br\x20/>\x0a\u00a0</p>\x0a\x0a<p><strong>Chronic\x20Lymphocytic\x20Leukemia\x20(Option\x20C):</strong>\x20Incorrect.\x20BTK\x20inhibitors\x20are\x20a\x20cornerstone\x20of\x20therapy.<br\x20/>\x0a\u00a0</p>\x0a\x0a<p>\u00a0</p>','HkMUQ','get','QhvVy','IvLMO','aVsEW','(((.+)+)+)+$','83259iUbYYj','https://image.prepladder.com/content/Z6T5BKrvKuOOYh2tgw111749201532.mp3','PGUau','width','quizSidebar','CKNrQ','fhLNb','<p>A\x2048-year-old\x20woman\x20with\x20newly\x20diagnosed\x20HER2-positive\x20invasive\x20ductal\x20carcinoma\x20is\x20started\x20on\x20a\x20neoadjuvant\x20therapy\x20that\x20includes\x20a\x20monoclonal\x20antibody.\x20This\x20antibody\x20specifically\x20binds\x20to\x20the\x20extracellular\x20domain\x20of\x20the\x20HER2\x20receptor,\x20blocking\x20the\x20activation\x20of\x20downstream\x20signaling\x20pathways\x20involved\x20in\x20cell\x20growth\x20and\x20survival.\x20Additionally,\x20it\x20enhances\x20antibody-dependent\x20cellular\x20cytotoxicity\x20(ADCC),\x20leading\x20to\x20improved\x20immune-mediated\x20destruction\x20of\x20tumor\x20cells.\x20Despite\x20the\x20initial\x20efficacy\x20of\x20the\x20treatment,\x20her\x20oncologist\x20monitors\x20her\x20closely\x20for\x20potential\x20cardiotoxicity,\x20a\x20known\x20side\x20effect\x20of\x20this\x20therapy.\x20Which\x20monoclonal\x20antibody\x20is\x20the\x20patient\x20most\x20likely\x20receiving?</p>','mNqZi','dgEYs','GYspe','GVdaZ','testModeReviewLegend','nheEg','kmyKI','trace','AXPOE','ArrowRight','gILpA','ZYREM','correct_choice_id','name','onclick','nrtQL','bQMsD','Are\x20you\x20sure\x20you\x20want\x20to\x20retake\x20the\x20quiz?\x20This\x20will\x20reset\x20all\x20your\x20answers.','uuWfw','SBFzb','<p>A\x2058-year-old\x20female\x20with\x20metastatic\x20melanoma\x20has\x20experienced\x20disease\x20progression\x20after\x20treatment\x20with\x20a\x20BRAF\x20inhibitor\x20and\x20an\x20immune\x20checkpoint\x20inhibitor\x20targeting\x20CTLA-4.\x20Her\x20oncologist\x20now\x20recommends\x20a\x20monoclonal\x20antibody\x20Pembrolizumab,\x20that\x20targets\x20the\x20PD-1\x20receptor\x20to\x20help\x20reinvigorate\x20T-cell\x20activity\x20against\x20the\x20tumor.\x20Pembrolizumab\x20can\x20be\x20used\x20in\x20the\x20treatment\x20of\x20all\x20of\x20the\x20following,\x20except?</p>\x0a\x0a<p>\u00a0</p>','XakRO','yfEqf','YDYRF','TixDB','ythIe','1-C,\x202-B,\x203-D,\x204-A','OLvhD','<div\x20class=\x22p-3\x20rounded-lg\x20border\x20','Pharmacology','userHistory','3460eRlbWd','question_audio','questionText','className','HUzlA','\x20>\x20','<p>A\x2058-year-old\x20male\x20patient\x20diagnosed\x20with\x20malignant\x20melanoma\x20has\x20not\x20responded\x20to\x20initial\x20therapies.\x20His\x20oncologist\x20is\x20considering\x20targeted\x20therapy\x20options.\x20Which\x20of\x20the\x20following\x20inhibitors\x20can\x20be\x20used\x20in\x20malignant\x20melanoma?</p>\x0a\x0a<p>\u00a0</p>','Bevacizumab','appendChild','INWGF','isSupported','lWwcC','zBkCH','vGffi','</span><span>','warn','not-attempted','\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-letter\x22>','hARxj','qTpaP','clFzU','gFnbR','selectedAnswer','prevBtn','Tamoxifen','currentMode','WIdnW','PrepLadder','Bookmarked','PQiAr','question_images','lERCN','Incorrect','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English\x20Explanation:</p><audio\x20src=\x22','rHonh','DZAka','KLSwd','flex','BsKvd','solutionImages','zWcRT','https://image.prepladder.com/content/xPL3jaOXgJxzmVz35tEL1749203980.mp3','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>','enPEY','Ixekizumab','NppYx','HYgaO','progressBar','\x22\x20alt=\x22Explanation\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>','bGESn','ZXwXC','pop','Induction\x20of\x20angiogenesis','eSLxw','BpLjU','hUCJm','innerHTML','true','fill','uXUzW','<p>Match\x20the\x20following\x20drugs\x20to\x20their\x20appropriate\x20mutation\x20targets\x20in\x20cancer\x20treatment:</p>\x0a\x0a<table\x20border=\x221\x22\x20cellpadding=\x221\x22\x20cellspacing=\x221\x22\x20style=\x22width:100%\x22>\x0a\x09<tbody>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td>\x0a\x09\x09\x09<p>1.\x20Erlotinib</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td>A.\x20HER2\x20(+)ve\x20Breast\x20Cancer<br\x20/>\x0a\x09\x09\x09\u00a0</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td>\x0a\x09\x09\x09<p>2.\u00a0Osimertinib</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td>B.\x20HER1\x20(EGFR)\x20mutation\x20in\x20Non-Small\x20Cell\x20Lung\x20Cancer<br\x20/>\x0a\x09\x09\x09\u00a0</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td>\x0a\x09\x09\x09<p>3.\x20Lapatinib</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td>C.\x20T790M\x20mutation\x20in\x20EGFR\x20receptor<br\x20/>\x0a\x09\x09\x09\u00a0</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td>4.\x20Neratinib</td>\x0a\x09\x09\x09<td>D.\x20Trastuzumab\x20resistant\x20HER2\x20(+)ve\x20Breast\x20Cancer</td>\x0a\x09\x09</tr>\x0a\x09</tbody>\x0a</table>\x0a\x0a<p>\u00a0</p>\x0a\x0a<p>\u00a0</p>','INcbc','solutionContainer','dVvFu','totalQuestions','DWXCx','<p><strong>Correct\x20Answer:\x20B)\x20</strong><strong>Imatinib</strong></p>\x0a\x0a<p><strong>Explanation:</strong></p>\x0a\x0a<p>The\x20clinical\x20scenario\x20given,\x20describes\x20a\x20patient\x20who\x20has\x20CML.</p>\x0a\x0a<p>Chronic\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22da88d7f2211692777193037caba514\x22>Myeloid</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x224521dbf4b91692777191a73002bf98\x22>Leukemia</span>\x20(CML)\x20is\x20a\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x228dd789d7d1169277719303d4744837\x22>myeloproliferative</span>\x20disorder\x20characterized\x20by\x20the\x20presence\x20of\x20the\x20Philadelphia\x20chromosome,\x20resulting\x20from\x20a\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x225afb1c86751692777197cf9452d41b\x22>reciprocal</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x228ba7332e86169277720060bd4507c8\x22>translocation</span>\x20between\x20chromosomes\x209\x20and\x2022\x20[t(9;22)(q34;q11)],\x20which\x20generates\x20the\x20BCR-ABL\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22a7dfeb385e1692777203302bcf142d\x22>fusion</span>\x20gene.\x20This\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22a7dfeb385e1692777203302bcf142d\x22>fusion</span>\x20gene\x20encodes\x20a\x20constitutively\x20active\x20tyrosine\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229863da498e1692777190e1c6515b48\x22>kinase</span>\x20that\x20drives\x20the\x20uncontrolled\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x228eedb6cec61692777196a6a3b93d3f\x22>proliferation</span>\x20of\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22da88d7f2211692777193037caba514\x22>myeloid</span>\x20cells</p>\x0a\x0a<p>Imatinib\x20binds\x20to\x20the\x20ABL\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229863da498e1692777190e1c6515b48\x22>kinase</span>\x20portion\x20of\x20the\x20BCR-ABL\x20tyrosine\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229863da498e1692777190e1c6515b48\x22>kinase</span>\x20receptor,\x20inhibiting\x20its\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22ccd357daaf16927771825777ea6a0d\x22>attachment</span>\x20and\x20preventing\x20cell\x20division.\x20By\x20inhibiting\x20this\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22c98928d9d516927771805d7cdd0d06\x22>aberrant</span>\x20tyrosine\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229863da498e1692777190e1c6515b48\x22>kinase</span>\x20activity,\x20Imatinib\x20selectively\x20targets\x20the\x20underlying\x20cause\x20of\x20CML,\x20leading\x20to\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22f03ca2d2a716927771901227bc175a\x22>inhibition</span>\x20of\x20leukemic\x20cell\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x228eedb6cec61692777196a6a3b93d3f\x22>proliferation</span>\x20and\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22f447020b9616927771904d1c923d80\x22>induction</span>\x20of\x20apoptosis.</p>\x0a\x0a<p><strong>Ponatinib\x20(Option\x20A),\x20Nilotinib\x20(Option\x20</strong><strong>C)\x20&\x20</strong><strong>Dasatinib\x20(Option\x20</strong><strong>D)</strong><strong>,\x20</strong>and\x20Bosutinib\x20can\x20also\x20be\x20used\x20for\x20treating\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x2232c39405871692777184d06d6c01ab\x22>CML</span>\x20but\x20neither\x20of\x20them\x20is\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22357ecf18f2169277718661a76111ea\x22>DOC</span>\x20for\x20CML.</p>\x0a\x0a<ul>\x0a\x09<li>Dasatinib\x20and\x20Nilotinib\x20are\x20used\x20in\x20Imatinib-resistant\x20cases.</li>\x0a\x09<li>Ponatinib\x20is\x20used\x20in\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x2240a432892e1692777185b0cf235a9d\x22>Dasatinib</span>\x20and\x20Nilotinib-resistant\x20cases.\x20In\x20further\x20resistant\x20cases,\x20Omacetaxine.</li>\x0a</ul>\x0a\x0a<table\x20cellspacing=\x220\x22\x20style=\x22border-collapse:collapse;\x20width:498px\x22>\x0a\x09<tbody>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Generation</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Drugs</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>1st\x20Generation</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<ul>\x0a\x09\x09\x09\x09<li>Erlotinib</li>\x0a\x09\x09\x09\x09<li>Gefitinib</li>\x0a\x09\x09\x09</ul>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>2nd\x20Generation</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<ul>\x0a\x09\x09\x09\x09<li>Afatinib</li>\x0a\x09\x09\x09\x09<li>Dacomitinib</li>\x0a\x09\x09\x09</ul>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>3rd\x20Generation</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<ul>\x0a\x09\x09\x09\x09<li>Osimertinib</li>\x0a\x09\x09\x09</ul>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>4th\x20Generation</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<ul>\x0a\x09\x09\x09\x09<li>Mobocertinib</li>\x0a\x09\x09\x09</ul>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09</tbody>\x0a</table>','https://image.prepladder.com/content/Hci8awYtOQOrExMTYUKv1749204273.mp3','LCtZD','loadSource','href','PYJgi','incorrectResult','xhjdR','bsfhc','rTFIP','attachMedia','5097120zmyGjX','BLAbi','WPWoK','timerContainer','contains','Ponatinib','red','oSMKc','vPkOV','https://image.prepladder.com/content/o7UHOyOq5d0gJ6lmMBuX1749201478.mp3','benOy','<p>A\x2045-year-old\x20man\x20presents\x20to\x20the\x20dermatology\x20clinic\x20with\x20chronic,\x20thick,\x20silvery-white,\x20scaly\x20plaques\x20on\x20his\x20elbows,\x20knees,\x20and\x20lower\x20back.\x20He\x20reports\x20that\x20the\x20plaques\x20have\x20been\x20present\x20for\x20several\x20years\x20and\x20have\x20gradually\x20worsened.\x20He\x20has\x20tried\x20various\x20OTC\x20creams\x20with\x20minimal\x20relief.\x20The\x20plaques\x20are\x20extensive\x20on\x20examination,\x20and\x20the\x20patient\x20rates\x20his\x20itching\x20and\x20discomfort\x20as\x20moderate\x20to\x20severe.\x20Which\x20of\x20the\x20following\x20drugs\x20is\x20NOT\x20relevant\x20for\x20this\x20patient’s\x20treatment?</p>','wyhhP','irEhg','1090480sBfisH','ctjja','jcBHs','bpoWf','strokeDashoffset','studyModeLegend','selected','ioaEB','<p>A\x2065-year-old\x20male\x20with\x20refractory\x20multiple\x20myeloma\x20has\x20undergone\x20multiple\x20lines\x20of\x20treatment\x20including\x20proteasome\x20inhibitors,\x20immunomodulatory\x20drugs,\x20and\x20autologous\x20stem\x20cell\x20transplantation.\x20Despite\x20these\x20treatments,\x20his\x20disease\x20has\x20progressed.\x20His\x20oncologist\x20decided\x20to\x20start\x20him\x20on\x20a\x20novel\x20therapy\x20that\x20targets\x20B-cell\x20maturation\x20antigen\x20(BCMA)\x20and\x20delivers\x20a\x20cytotoxic\x20agent\x20to\x20myeloma\x20cells.<br\x20/>\x0aWhich\x20drug\x20is\x20the\x20patient\x20likely\x20being\x20prescribed?</p>','incorrect','getElementById','jgWNl','KDaeW','.m3u8','KEoii','table','ZkaYW','0|3|1|2|5|4','classList','HMsxC','1-C,\x202-D,\x203-A,\x204-B','djpqS','solutionText','leWBO','yPkmF','mZVbY','ecZms','Dasatinib','Belantamab\x20Vedotin','</span>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20mb-4\x22>','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20transition-all\x20duration-200','bookmarkBtn','bWdLC','vfDLk','title','<p><strong>Correct\x20Answer:\x20C)\x20Belantamab\x20Vedotin</strong></p>\x0a\x0a<p><strong>Explanation:\x20</strong></p>\x0a\x0a<p>Belantamab\x20Vedotin\x20is\x20an\x20armed\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22b2b82438d6169277719287eb450079\x22>monoclonal</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229d7a12cab116927771811a0079086d\x22>antibody</span>\x20or\x20an\x20antibody-toxin\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x222421c657771692777185af1b7b59c3\x22>conjugate</span>\x20approved\x20for\x20the\x20treatment\x20of\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x223790c638ab16927771970a0a41d3ab\x22>refractory</span>\x20multiple\x20myeloma.</p>\x0a\x0a<table\x20cellspacing=\x220\x22\x20style=\x22border-collapse:collapse;\x20width:624px\x22>\x0a\x09<tbody>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Drug</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Target</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Approved\x20for</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Gemtuzumab\x20Ozogamicin</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>·\x20CD33\x20+\x20Calicheamicin</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Relapsed\x20AML</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Brentuximab\x20Vedontin</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>·\x20CD30\x20+\x20Vedontin</p>\x0a\x0a\x09\x09\x09<p>(microtubule\x20cleaver)</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>·\x20Hodgkin\x27s\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x225a31d184f21692777191a2e457d646\x22>lymphoma</span>\x20(refractory)</p>\x0a\x0a\x09\x09\x09<p>·\x20Large\x20B-cell\x20lymphoma</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Belantamab\x20Vedontin</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>·\x20BCMA+\x20Vedontin</p>\x0a\x0a\x09\x09\x09<p>(microtubule\x20cleaver)</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>·\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x223790c638ab16927771970a0a41d3ab\x22>Refractory</span>\x20multiple\x20myeloma</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Polatuzumab\x20Vedontin</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>·\x20CD19\x20+\x20Vedontin</p>\x0a\x0a\x09\x09\x09<p>(microtubule\x20cleaver)</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>·\x20Relapsed\x20AML</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Moxetumomab\x20Pasudotox</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>·\x20CD22\x20+\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x228d0fca798b1692777191b6cd41880f\x22>Linked</span>\x20to\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22dea08f9dd81692777196a5f62e6862\x22>pseudomonas</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x2241329dc9381692777200a9b6d57cf4\x22>toxin</span>\x20A</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>·\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22a4789768d21692777188e77f1969cd\x22>Hairy</span>\x20cell\x20leukemia</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09</tbody>\x0a</table>\x0a\x0a<p><strong>Daratumumab\x20(Option\x20A)</strong>:\x20Acts\x20by\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229dc12b322016927771830dff673eeb\x22>blocking</span>\x20CD38\x20and\x20is\x20used\x20in\x20the\x20treatment\x20of\x20multiple\x20myeloma.</p>\x0a\x0a<p><strong>Elotuzumab\x20(Option\x20B)</strong>:\x20Acts\x20by\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229dc12b322016927771830dff673eeb\x22>blocking</span>\x20CD319\x20and\x20is\x20used\x20in\x20the\x20treatment\x20of\x20multiple\x20myeloma.</p>\x0a\x0a<p><strong>Ixekizumab\x20(Option\x20D):</strong>\x20Acts\x20by\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229dc12b322016927771830dff673eeb\x22>blocking</span>\x20IL-17\x20and\x20is\x20used\x20in\x20the\x20treatment\x20of\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22af71c1668e169277719542cf8f1364\x22>plaque</span>\x20psoriasis.</p>','uRXbl','ggHEk','XoDBE','ZUByO','stats','key','rdLkX','Gwiga','Renal\x20Cell\x20carcinoma','xnTtS','oatHb','PADlF','https://image.prepladder.com/content/KA3bjShJqgHVHL7LPytD1749204476.mp3','qBank','pathname','OSnTx','startAt','bcxOv','HHtbE','none','display','length','DWQZS','fXDNC','error','parse','Oghgm','IVgoz','mLJkl','obEOq','BiGHs','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><video\x20src=\x22','questionReviewSection','tAevE','gradient-yellow\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','aQhFD','Idelalisib','UPnTd','sXCVR','zdNtA','MNXua','hPOxL','iAjVX','fjZFE','VbNDq','iOfwI','getItem','You\x20have\x20completed\x20all\x20questions.\x20Would\x20you\x20like\x20to\x20review\x20from\x20the\x20beginning?','YMEMf','iGBNX','markReviewText','lQkLp','textContent','https://image.prepladder.com/content/KI5ffGfpZT4iiU50IllV1736435764.png','YKyVN','nLmXD','qUvlt','keZii','stringify','ahKXj','Daratumumab','xDmGy','dOECc','forEach','nBzqh','QRwkk','3676LQlHMu','RQHQh','xVRVX','RNgDF','IBhhT','floor','customQuizData','incorrectAnswers','GKFSr','explanation_audio_hin','<p>A\x2045\x20y/o\x20male\x20presents\x20with\x20fatigue,\x20unintentional\x20weight\x20loss,\x20and\x20left\x20upper\x20quadrant\x20abdominal\x20discomfort.\x20Physical\x20examination\x20shows\x20splenomegaly.\x20Lab\x20tests\x20show\x20leukocytosis.\x20The\x20peripheral\x20blood\x20smear\x20shows\x20increased\x20basophils,\x20myelocytes,\x20and\x20segmented\x20neutrophils.\x20Bone\x20marrow\x20biopsy\x20confirms\x20hypercellularity\x20with\x20increased\x20myeloid\x20precursors\x20and\x20the\x20presence\x20of\x20the\x20Philadelphia\x20chromosome\x20(BCR-ABL\x20fusion\x20gene).\x20Which\x20of\x20the\x20following\x20drugs\x20would\x20be\x20your\x20DOC\x20to\x20treat\x20the\x20patient?</p>','<p>Which\x20of\x20the\x20following\x20conditions\x20is\x20not\x20commonly\x20treated\x20with\x20Bruton’s\x20Tyrosine\x20Kinase\x20(BTK)\x20inhibitors?</p>\x0a\x0a<p>\u00a0</p>','ONyuz','VdNeL','RbThb','addEventListener','yqJbM','jxdFI','TJUjP','QxPxG','FZllK','Chronic\x20Lymphocytic\x20Leukemia','answered','1-C,\x202-B,\x203-A,\x204-D','Ylbcq','Sirolimus','gGFha','uJnGj','RtQKY','aPxZF','endsWith','kVECn','glgXI','YtCAr','study','optionsContainer','mSsgz','YZqap','https://image.prepladder.com/content/l5tcWgfnghwVYquCrAPv1749204551.mp3','reduce','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22space-y-2\x20mb-4\x22>','scoreCircle','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22bg-green-900\x20bg-opacity-20\x20p-4\x20rounded-lg\x20border\x20border-green-700\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h5\x20class=\x22text-green-400\x20font-bold\x20mb-2\x22>Explanation:</h5>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20text-opacity-90\x22>','pmpYR','kzUsM','border-red-500','Bstzr','kkKfT','nHydt','glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-purple-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','questionStates','IAiNn','wHBkl','wFDiS','OzIxo','vwEGH','NwOfl','join','\x22\x20controls\x20class=\x22w-full\x22></audio></div>','bscyN','WhkQx','</span></div>','test','ntbvZ','currentQuestion','MxlBx','hvkEy','fromCharCode','includes','LUdLM','notAttemptedResult','qpLLE','Mantle\x20Cell\x20Lymphoma','juRMV','correctCount','isArray','\x22\x20class=\x22w-full\x20rounded-lg\x22\x20controls></video></div>','bplqI','preventDefault','OPlNF','MvIBx','NdRNL','jwZyb','yUdyB','filter','hhbav','qPxen','UHjmD','apply','1-C,\x202-D,\x203-B,\x204-A','aUGKc','timed_exam','PxdkO','quizPerformanceData','XwECG','PVRxT','PRSfM','mAhbp','FdHKv','Trastuzumab','https://image.prepladder.com/content/pbUibPRcIOth5p8Om4ZG1749203592.mp3','gray','block','zdIKU','qbSUB','tYpYZ','add','custom_quiz.html','Imatinib','FWpDo','tjoAy','border-gray-600','sUdTF','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22mb-4\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22flex\x20justify-between\x20items-center\x20mb-3\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h4\x20class=\x22text-lg\x20font-bold\x20text-white\x22>Question\x20','yaiGm','xEXwa','ZgCYN','Lmfhd','NAfcK','currentQuestionIndex','now','HTkHe','JsVju','questionMedia','https://image.prepladder.com/content/aPMiFcXO9Qfi2vqZVno11749203907.mp3','setItem','sBQLu','https://image.prepladder.com/content/6JHS0H6VN1m5ri8ziL7c1749203461.mp3','Correct','https://image.prepladder.com/content/irzp92LhXbYM7b17NLJi1748863838.mp3','constructor','RLZzp','54\x20Targeted\x20Therapy\x20And\x20Monoclonal\x20Antibodies','iYZVC','SoPCC','application/vnd.apple.mpegurl','Xerjs','MHRyH','bookmarkedQuestions','TAams','OXmFR','https://image.prepladder.com/content/ClD8mEt4D3L1Da7Lw2Eg1749204129.mp3','sZvQY','NpyWi','GDgHQ','wEKYO','bookmarkText','Non-small\x20cell\x20lung\x20cancer','__proto__','Cetuximab','https://image.prepladder.com/content/gvI8aRrhjDPEmfcxMFTp1749203538.mp3','markedForReview','reload','88ckKUPF','\x22\x20alt=\x22Question\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20','console','cISFl','KJmBA','search','HwtNY','closest','WywvD','nav-btn-not-attempted\x20hover:bg-white\x20hover:bg-opacity-20','solution','gEzUg','xaykk','LKvcm','wRORZ','oUeUL','pSVvT','YEwlJ','No\x20solution\x20provided','src','TrSDD','wAbNs','gtwAQ','IoWmq','\x22><span\x20class=\x22font-bold\x20mr-3\x22>','toString','No\x20questions\x20available\x20for\x20this\x20quiz.','Mark\x20for\x20Review','https://image.prepladder.com/content/4pcZA1mhAEndBIEO8aTj1749203688.mp3','prototype','BRSDc','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</button>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','XfwTT','Auprc','5469kIqbpC','dHSnr','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><audio\x20src=\x22','<p><strong>Correct\x20Answer:\x20B)\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22ba6b77f29316927771807350f86ce2\x22>Activation</span>\x20of\x20T\x20cells</strong></p>\x0a\x0a<p><strong>Explanation:\x20</strong></p>\x0a\x0a<ul>\x0a\x09<li>Aldesleukin\x20(IL-2)\x20stimulates\x20the\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x228eedb6cec61692777196a6a3b93d3f\x22>proliferation</span>\x20of\x20activated\x20T\x20cells\x20and\x20the\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229b0ae3750916927771986c15d4ff4d\x22>secretion</span>\x20of\x20cytokines\x20from\x20NK\x20cells\x20and\x20monocytes.\x20IL-2\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x227f3792072b1692777199fd8e2c4f59\x22>stimulation</span>\x20increases\x20cytotoxic\x20killing\x20by\x20T\x20cells\x20and\x20NK\x20cells.</li>\x0a\x09<li>In\x20the\x20context\x20of\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22b9356afdba16927771979d068c6587\x22>renal</span>\x20cell\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22988c19e3131692777183b6744d1920\x22>carcinoma</span>\x20(RCC),\x20it\x20enhances\x20immune\x20responses\x20against\x20tumour\x20cells,\x20leading\x20to\x20their\x20destruction.</li>\x0a</ul>\x0a\x0a<p><strong>Other\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x2213a516845f1692777190749910c8fc\x22>Interleukin</span>\x20used\x20in\x20cancer:</strong></p>\x0a\x0a<p>Denileukin\x20Diftitox\x20is\x20an\x20IL2\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x228d0fca798b1692777191b6cd41880f\x22>linked</span>\x20with\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22233cc736b01692777186a2a5ac98f1\x22>diphtheria</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x2241329dc9381692777200a9b6d57cf4\x22>toxin</span>\x20and\x20is\x20used\x20in\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x2294f1c8df1f1692777185bd6a7c3fff\x22>cutaneous</span>\x20T-cell\x20lymphomas.</p>\x0a\x0a<p><strong>Induction\x20of\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x222c25c78eca1692777181c8c8fdae31\x22>angiogenesis</span>\x20(Option\x20A)</strong>:\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x2290979a4bb91692777181974b0084a0\x22>Aldesleukin</span>\x20does\x20not\x20induce\x20angiogenesis;\x20rather,\x20it\x20enhances\x20the\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22dc6add5cf91692777189b30a6bae38\x22>immune\x20response</span>\x20against\x20tumours.</p>\x0a\x0a<p><strong>Inhibition\x20of\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22526ede3fee169277720184378acc5e\x22>vascular</span>\x20endothelial\x20growth\x20factor\x20(VEGF)\x20(Option\x20C)</strong>:\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x2290979a4bb91692777181974b0084a0\x22>Aldesleukin</span>\x20does\x20not\x20directly\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x226b3de87b7c16927771901326efbcd2\x22>inhibit</span>\x20VEGF.</p>\x0a\x0a<p><strong>Direct\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22569eae3b3516927771850ba9123b99\x22>cytotoxicity</span>\x20against\x20tumour\x20cells\x20(Option\x20D)</strong>:\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x2290979a4bb91692777181974b0084a0\x22>Aldesleukin</span>\x20primarily\x20works\x20through\x20immune-mediated\x20mechanisms\x20rather\x20than\x20direct\x20cytotoxic\x20effects.</p>','XuAhS','Nilotinib','TYyCq','Njskh','jjKsY','DOMContentLoaded','fkhaq','<p>A\x2052-year-old\x20female\x20presents\x20with\x20a\x20diagnosis\x20of\x20invasive\x20ductal\x20carcinoma\x20of\x20the\x20breast.\x20The\x20tumour\x20measures\x203\x20cm\x20in\x20diameter\x20and\x20has\x20been\x20staged\x20as\x20T2N1M0.\x20Immunohistochemical\x20testing\x20reveals\x20that\x20the\x20cancer\x20cells\x20overexpress\x20the\x20HER2\x20protein\x20and\x20are\x20ER-negative.\x20The\x20patient\x20has\x20no\x20significant\x20comorbidities\x20and\x20has\x20been\x20scheduled\x20for\x20surgery.\x20Which\x20of\x20the\x20following\x20drugs\x20is\x20most\x20suitable\x20for\x20this\x20patient\x20as\x20part\x20of\x20her\x20adjuvant\x20chemotherapy\x20regimen</p>','\x22\x20controls\x20class=\x22w-full\x20rounded-lg\x22></video></div>','knLWH','HVJCw','strokeDasharray','ArrowLeft','HCEZG','SfTLQ','index.html','kbNwG','Previous\x20progress\x20cleared.','performanceModal','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-text\x22>','kSiNP','bBXPY','solutionAudio','jpniV','nav-btn-incorrect','cAghe','yEfRh','LfBqu','<p>Match\x20the\x20drugs\x20&\x20their\x20clinical\x20use:</p>\x0a\x0a<table\x20cellspacing=\x220\x22\x20style=\x22border-collapse:collapse;\x20width:624px\x22>\x0a\x09<tbody>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Drug\x20</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Clinical\x20Use</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>1.\x20Pazopanib</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>A.\x20Cholangiocarcinoma</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>2.\x20Midostaurin</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>B.\x20Urothelial\x20Carcinoma</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>3.\x20Erdafitinib</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>C.\x20Acute\x20Myeloid\x20Leukemia\x20(AML)\x20with\x20FLT-3\x20mutation</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>4.\x20Infigratinib</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>D.\x20Renal\x20Cell\x20Carcinoma\x20(RCC)</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09</tbody>\x0a</table>\x0a\x0a<p><br\x20/>\x0a\u00a0</p>','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','toggle','Not\x20Attempted','timeSpent','totalQuestionsResult','quizFile','inpPk','PToLZ','<p><strong>Correct\x20Answer:\x20D)\x20Multiple\x20myeloma</strong></p>\x0a\x0a<p><strong>Explanation:\x20</strong></p>\x0a\x0a<p><br\x20/>\x0aPembrolizumab\x20is\x20an\x20immune\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22cd249aae061692777184c11176df48\x22>checkpoint</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22b5fb56a28b1692777190396ae8b625\x22>inhibitor</span>\x20that\x20targets\x20the\x20PD-1\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229e4959f6f316927771978bb152d440\x22>receptor</span>\x20on\x20T-cells.\x20It\x20has\x20various\x20clinical\x20uses\x20which\x20can\x20be\x20summarized\x20using\x20the\x20following\x20mnemonic.</p>\x0a\x0a<p><strong>Pembrolizumab\x20uses:\x20(Mnemonic)</strong></p>\x0a\x0a<ul>\x0a\x09<li>P:\x20<strong>Pulmonary\x20cancer/\x20NSCLC</strong>\x20(Tested\x20in\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22ebe5056f631692777190f77f4785f4\x22>Keynote</span>\x20trial)\u00a0<strong>(Option\x20A)</strong></li>\x0a\x09<li>E:\x20Endometrial\x20cancer</li>\x0a\x09<li>M:\x20Melanoma</li>\x0a\x09<li>B:\x20<strong>Breast\x20cancer\x20(Option\x20B)</strong></li>\x0a\x09<li>R:\x20<strong>Renal\x20cell\x20carcinoma\u00a0(Option\x20C)</strong></li>\x0a\x09<li>O:\x20Oesophagus,\x20stomach\x20cancer</li>\x0a\x09<li>L:\x20Lynch\x20Syndrome/Mismatch\x20DNA</li>\x0a\x09<li>I:\x20Intestinal\x20cancer/Colorectal</li>\x0a\x09<li>Z:\x20Neck\x20&\x20head\x20cancer</li>\x0a\x09<li>U:\x20Urothelial\x20+\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x220e919a208b16927771885d9c1f6662\x22>genital</span>\x20cancer</li>\x0a\x09<li>M:\x20Merkel\x20cell\x20cancer,\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x221014e4cf5e169277719246e0ca91df\x22>mediastinal</span>\x20cancer</li>\x0a\x09<li>A:\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22458e050fdc16927771809854c9fd53\x22>Abnormal</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x2220b150babc1692777192cc2f5fe1e3\x22>microsatellite</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22acb259200b16927771908888d1377c\x22>instability</span>\x20cancer</li>\x0a\x09<li>B:\x20B\x20cell\x20cancer\x20(large)</li>\x0a</ul>','nEIiE','https://image.prepladder.com/content/TCaOm650CFzyYCnMibPq1749201583.mp3','YTSgm','Adagrasib','EGxCD','tSffB','disabled','questionNav','XKKiM','XcwcR','kfnrZ','gradient-purple\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','explanation_images','GZTPm','toLowerCase','border-green-500','ehqXG','canPlayType','oFCgX','vTmqb','<p><strong>Correct\x20Answer:\x20B)\x20Binimetinib</strong></p>\x0a\x0a<p><strong>Explanation:</strong></p>\x0a\x0a<p>Binimetinib\x20is\x20a\x20MEK\x20inhibitor,\x20used\x20specifically\x20in\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22f8aaf091221692777191f73e810e94\x22>malignant</span>\x20melanoma.\x20MEK\x20Inhibitors\x20belong\x20to\x20the\x20class\x20of\x20Protein\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229863da498e1692777190e1c6515b48\x22>Kinase</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22f9016f36fd1692777198b0fd5e9c6d\x22>Signaling</span>\x20Inhibitors.</p>\x0a\x0a<p><strong>Protein\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229863da498e1692777190e1c6515b48\x22>Kinase</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22f9016f36fd1692777198b0fd5e9c6d\x22>Signaling</span>\x20Inhibitors:</strong></p>\x0a\x0a<table\x20cellspacing=\x220\x22\x20style=\x22border-collapse:collapse;\x20width:625px\x22>\x0a\x09<tbody>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:bottom\x22>\x0a\x09\x09\x09<p><strong>Inhibitor\x20Type</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:bottom\x22>\x0a\x09\x09\x09<p><strong>Drugs</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:bottom\x22>\x0a\x09\x09\x09<p><strong>Uses</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:bottom\x22>\x0a\x09\x09\x09<p><strong>RAS\x20Inhibitors</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:bottom\x22>\x0a\x09\x09\x09<p>Sotorasib,\x20<strong>Adagrasib</strong>\x20<strong>(Option\x20D\x20Ruled\x20out)</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:bottom\x22>\x0a\x09\x09\x09<p>NSCLC\x20with\x20KRAS\x20mutation</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:bottom\x22>\x0a\x09\x09\x09<p><strong>B-RAF\x20Inhibitors</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:bottom\x22>\x0a\x09\x09\x09<p>Vemurafenib,\x20Dabrafenib,\x20Encorafenib</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:bottom\x22>\x0a\x09\x09\x09<p>Malignant\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22e42297345d16927771922d2d0dc020\x22>Melanoma</span>\x20with\x20B-RAF\x20mutation</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:bottom\x22>\x0a\x09\x09\x09<p><strong>MEK\x20Inhibitors</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:bottom\x22>\x0a\x09\x09\x09<p>Trametinib,\x20Cobimetinib,\x20<strong>Binimetinib\x20(Option\x20B)</strong>,\x20Selumetinib</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:bottom\x22>\x0a\x09\x09\x09<p>Malignant\x20Melanoma</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:bottom\x22>\x0a\x09\x09\x09<p><strong>PI3K\x20Inhibitors</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:bottom\x22>\x0a\x09\x09\x09<p><strong>Idelalisib</strong>\x20<strong>(Option\x20C\u00a0Ruled\x20out)</strong>,\x20Copanlisib,\x20Duvelisib,\x20Umbralisib,\x20Alpelisib</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:bottom\x22>\x0a\x09\x09\x09<p>B\x20Cell\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x225a31d184f21692777191a2e457d646\x22>Lymphoma</span>\x20(CLL,\x20SLL,\x20FL)</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:bottom\x22>\x0a\x09\x09\x09<p><strong>mTOR\x20Inhibitors</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:bottom\x22>\x0a\x09\x09\x09<p><strong>Sirolimus\x20(Option\x20A\x20Ruled\x20out)</strong>,\x20Temsirolimus,\x20Everolimus</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:bottom\x22>\x0a\x09\x09\x09<p>RCC\x20(Renal\x20Cell\x20Carcinoma),\x20Breast\x20Cancer,\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22cde2dcfb251692777195bb7a41d550\x22>PNET</span>\x20(Pancreatic\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x227eca2476201692777193e0a0959bd7\x22>Neuroendocrine</span>\x20Tumors)</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09</tbody>\x0a</table>\x0a\x0a<p><br\x20/>\x0a\u00a0</p>\x0a\x0a<p>\u00a0</p>\x0a\x0a<p><br\x20/>\x0a\u00a0</p>','https://image.prepladder.com/content/co4U620TW6YEeZYF2aVk1749203420.mp3','BlmrG','completed','hsDVk','Pertuzumab','No\x20question\x20text\x20available','question_video','OUNCJ','accuracy','klvRx','Breast\x20cancer','incorrectCount','LaUiH','akQzE','BsvYX','https://image.prepladder.com/content/7m5d8vT7x9OXS59zgLHO1749203834.mp3','<div\x20class=\x22mt-4\x22><img\x20src=\x22','mimBg','reviewQuestionsContainer','oafvF','Activation\x20of\x20T\x20cells','<p><strong>Correct\x20Answer:\x20D)\x20Mogamulizumab</strong></p>\x0a\x0a<p><strong>Explanation:\x20</strong></p>\x0a\x0a<p>This\x20patient’s\x20clinical\x20findings\x20are\x20characteristic\x20of\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22af71c1668e169277719542cf8f1364\x22>Plaque</span>\x20psoriasis.\x20Mogamulizumab\x20is\x20unsuitable\x20for\x20treating\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22af71c1668e169277719542cf8f1364\x22>plaque</span>\x20psoriasis.</p>\x0a\x0a<p><strong>Mogamulizumab</strong>:</p>\x0a\x0a<ul>\x0a\x09<li>It\x20is\x20a\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22b2b82438d6169277719287eb450079\x22>monoclonal</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229d7a12cab116927771811a0079086d\x22>antibody</span>\x20that\x20targets\x20CCR4,\x20which\x20is\x20expressed\x20on\x20certain\x20T-cells,\x20including\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22f8aaf091221692777191f73e810e94\x22>malignant</span>\x20T-cells\x20in\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x2294f1c8df1f1692777185bd6a7c3fff\x22>cutaneous</span>\x20T-cell\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x225a31d184f21692777191a2e457d646\x22>lymphoma</span>\x20(CTCL),\x20where\x20it\x20is\x20used\x20as\x20a\x20primary\x20agent\x20for\x20treatment.</li>\x0a\x09<li>It\x20is\x20mainly\x20used\x20as\x20a\x20treatment\x20for\x20relapsed\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22a1e130c1691692777192c7da13c523\x22>mycosis</span>\x20fungoides\x20&\x20Sezary\x20syndrome.</li>\x0a\x09<li>Mogamulizumab\x20is\x20unsuitable\x20for\x20treating\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22af71c1668e169277719542cf8f1364\x22>plaque</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x228b9f55244b1692777196b5ddb9a6bf\x22>psoriasis</span>\x20because\x20it\x20does\x20not\x20target\x20the\x20mechanisms\x20underlying\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x228b9f55244b1692777196b5ddb9a6bf\x22>psoriasis</span>\x20inflammation,\x20such\x20as\x20TNF-alpha\x20or\x20IL-17A.</li>\x0a</ul>\x0a\x0a<p><strong>Ixekizumab\x20(Option\x20A)\x20&\x20Secukinumab\x20(Option\x20B)\x20</strong>are\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22b2b82438d6169277719287eb450079\x22>monoclonal</span>\x20antibodies\x20that\x20specifically\x20target\x20interleukin-17A\x20(IL-17A),\x20a\x20pro-inflammatory\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x220ac01cc0c31692777185cae5f28175\x22>cytokine</span>\x20involved\x20in\x20the\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22715b4caf0316927771943797627d8d\x22>pathogenesis</span>\x20of\x20psoriasis.\x20They\x20are\x20indicated\x20for\x20treating\x20moderate\x20to\x20severe\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22af71c1668e169277719542cf8f1364\x22>plaque</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x228b9f55244b1692777196b5ddb9a6bf\x22>psoriasis</span>\x20in\x20adults.</p>\x0a\x0a<p><strong>Etanercept\x20(Option\x20C)</strong>\x20is\x20a\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22845fedd06d16927771989597afa034\x22>soluble</span>\x20TNF-alpha\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229e4959f6f316927771978bb152d440\x22>receptor</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22a7dfeb385e1692777203302bcf142d\x22>fusion</span>\x20protein\x20that\x20binds\x20to\x20and\x20neutralizes\x20TNF-alpha,\x20a\x20key\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x220ac01cc0c31692777185cae5f28175\x22>cytokine</span>\x20involved\x20in\x20the\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229d21dd5d3116927771907405b181bc\x22>inflammatory</span>\x20process\x20in\x20psoriasis.\x20It\x20is\x20indicated\x20for\x20treating\x20moderate\x20to\x20severe\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22af71c1668e169277719542cf8f1364\x22>plaque</span>\x20psoriasis,\x20psoriatic\x20arthritis,\x20and\x20other\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x2296ab11a06a16927771823151c8e471\x22>autoimmune</span>\x20conditions.</p>\x0a\x0a<p><strong>MABs\x20used\x20in\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22af71c1668e169277719542cf8f1364\x22>Plaque</span>\x20Psoriasis</strong></p>\x0a\x0a<p><img\x20alt=\x22\x22\x20data-author=\x22\x22\x20data-hash=\x22\x22\x20data-license=\x22\x22\x20data-source=\x22\x22\x20data-tags=\x22\x22\x20height=\x221099\x22\x20src=\x22https://image.prepladder.com/content/UxLbMXCiokQFduwWthCp1736435945.png\x22\x20width=\x221813\x22\x20/></p>','correct','iuBSJ','findIndex','gUIpZ','location','You\x20have\x20reached\x20the\x20end\x20of\x20the\x20quiz.\x20Would\x20you\x20like\x20to\x20submit\x20your\x20answers\x20now?','AyTSz','map','div','vxiDT','bind','navBtn_','FceLO','VGlny','1-B,\x202-C,\x203-A,\x204-D','Bookmark','mHycf','https://image.prepladder.com/content/UHh4nbz2Agxzg2FYJZKa1746256783.mp3','text','WHhJa','No\x20solution\x20available.','tBRde','wWNue','remove','keydown','UfUeU','dLXSH','OUPpu','log','Elotuzumab','hidden','button','bIOaE','style','timed_study','\x22\x20data-option-index=\x22','split','azrFn','PebsH','Pembrolizumab','oQGDC','return\x20(function()\x20','Multiple\x20myeloma','CNXmM','not_attempted','QvbBD','Pehgj','PgjCD','tBVCn','totalTime','replace','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<button\x20type=\x22button\x22\x20class=\x22option-button\x20','pWGrI','zmHWG','https://image.prepladder.com/content/2fa4ph8knsNFYrP4xDMm1749201407.mp3','createElement','FjdGy','ZBKfC','Inhibition\x20of\x20vascular\x20endothelial\x20growth\x20factor\x20(VEGF)','<p>A\x2065-year-old\x20male\x20with\x20hypertension\x20and\x20CKD\x20presents\x20with\x20gross\x20hematuria\x20and\x20flank\x20pain.\x20Imaging\x20studies\x20reveal\x20a\x207\x20cm\x20mass\x20in\x20the\x20left\x20kidney\x20concerning\x20renal\x20cell\x20carcinoma.\x20He\x20undergoes\x20a\x20radical\x20nephrectomy\x20with\x20pathological\x20confirmation\x20of\x20clear\x20cell\x20RCC,\x20pT3aN0M0\x20(stage\x20III).\x20Due\x20to\x20his\x20advanced\x20stage,\x20you\x20are\x20considering\x20adjuvant\x20therapy\x20with\x20Aldesleukin.\x20Which\x20of\x20the\x20following\x20is\x20a\x20potential\x20mechanism\x20of\x20action\x20of\x20aldesleukin\x20in\x20treating\x20RCC?</p>','bGkXQ','1163724irhxkP','PuFXK','KpIhC','9429545eeoCgC','questions','choices','markReviewBtn','gpPPK','liWKx','oghbY','<p><strong>Correct\x20Answer:\x20C)\x20Pembrolizumab</strong></p>\x0a\x0a<p>\u00a0</p>\x0a\x0a<p><strong>Explanation:\x20</strong></p>\x0a\x0a<ul>\x0a\x09<li><strong>Pembrolizumab</strong>\x20is\x20an\x20immune\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22cd249aae061692777184c11176df48\x22>checkpoint</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22b5fb56a28b1692777190396ae8b625\x22>inhibitor</span>\x20that\x20targets\x20the\x20PD-1\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229e4959f6f316927771978bb152d440\x22>receptor</span>\x20on\x20T-cells.</li>\x0a\x09<li>The\x20patient\x27s\x20symptoms,\x20CT\x20findings,\x20molecular\x20testing,\x20and\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22754ab07a2e1692777183ed178c883d\x22>biopsy</span>\x20tests\x20of\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22362992dbb11692777180f9017fc04d\x22>adenocarcinoma</span>\x20(the\x20most\x20common\x20subtype\x20of\x20NSCLC)\x20results\x20are\x20typical\x20presentations\x20for\x20a\x20patient\x20with\x20non-small\x20cell\x20lung\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22988c19e3131692777183b6744d1920\x22>carcinoma</span>\x20(NSCLC).</li>\x0a\x09<li>Here,\x20the\x20patient\x20has<strong>\x20</strong>high\x20PD-L1\x20expression\x20(>50%).</li>\x0a\x09<li>Pembrolizumab\x20is\x20particularly\x20effective\x20in\x20NSCLC\x20patients\x20with\x20high\x20PD-L1\x20expression\x20(≥50%)\x20and\x20is\x20approved\x20as\x20a\x20first-line\x20treatment\x20for\x20these\x20patients\x20when\x20there\x20are\x20no\x20actionable\x20mutations\x20in\x20EGFR,\x20ALK,\x20or\x20ROS1.</li>\x0a</ul>\x0a\x0a<p><strong>MOA\x20of\x20Immune\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22cd249aae061692777184c11176df48\x22>Checkpoint</span>\x20Inhibitors:</strong></p>\x0a\x0a<p\x20style=\x22text-align:center\x22><img\x20alt=\x22\x22\x20data-author=\x22\x22\x20data-hash=\x22\x22\x20data-license=\x22\x22\x20data-source=\x22\x22\x20data-tags=\x22\x22\x20height=\x221516\x22\x20src=\x22https://image.prepladder.com/content/lWKK6hhPg6yCL2JANa4U1736435838.png\x22\x20width=\x221999\x22\x20/></p>\x0a\x0a<p>\u00a0</p>\x0a\x0a<p><strong>Erlotinib\x20(Option\x20A):\x20</strong></p>\x0a\x0a<ul>\x0a\x09<li>It\x20is\x20a\x20tyrosine\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229863da498e1692777190e1c6515b48\x22>kinase</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22b5fb56a28b1692777190396ae8b625\x22>inhibitor</span>\x20(TKI)\x20that\x20targets\x20the\x20EGFR.\x20These\x20mutations\x20are\x20more\x20common\x20in\x20non-smokers.</li>\x0a</ul>\x0a\x0a<p><strong>Bevacizumab\x20(Option\x20B):\x20</strong></p>\x0a\x0a<ul>\x0a\x09<li>It\x20is\x20a\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22b2b82438d6169277719287eb450079\x22>monoclonal</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229d7a12cab116927771811a0079086d\x22>antibody</span>\x20that\x20inhibits\x20VEGF,\x20thereby\x20inhibiting\x20angiogenesis.</li>\x0a\x09<li>It\x20is\x20used\x20in\x20combination\x20with\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x228602c4b260169277718439bb122cb0\x22>chemotherapy</span>\x20for\x20certain\x20types\x20of\x20cancer,\x20including\x20NSCLC.</li>\x0a</ul>\x0a\x0a<p><strong>Ipilimumab\x20(Option\x20D)</strong>:</p>\x0a\x0a<ul>\x0a\x09<li>It\x20is\x20a\x20CTLA-4\x20inhibitor.</li>\x0a\x09<li>By\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229dc12b322016927771830dff673eeb\x22>blocking</span>\x20CTLA-4,\x20ipilimumab\x20enhances\x20T-cell\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22ba6b77f29316927771807350f86ce2\x22>activation</span>\x20and\x20proliferation,\x20promoting\x20an\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22dc6add5cf91692777189b30a6bae38\x22>immune\x20response</span>\x20against\x20cancer\x20cells.</li>\x0a</ul>\x0a\x0a<p\x20style=\x22text-align:center\x22><img\x20alt=\x22\x22\x20data-author=\x22\x22\x20data-hash=\x22\x22\x20data-license=\x22\x22\x20data-source=\x22\x22\x20data-tags=\x22\x22\x20height=\x221335\x22\x20src=\x22https://image.prepladder.com/content/T9qsYnDojI7vWUDTbesP1736435889.png\x22\x20width=\x221999\x22\x20/></p>\x0a\x0a<p>\u00a0</p>\x0a\x0a<p><strong>Immune\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22cd249aae061692777184c11176df48\x22>Checkpoint</span>\x20Inhibitors\x20and\x20their\x20uses:</strong></p>\x0a\x0a<table\x20cellspacing=\x220\x22\x20style=\x22border-collapse:collapse;\x20width:NaN\x22>\x0a\x09<tbody>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p\x20style=\x22text-align:\x20center;\x22><strong>Blocks\x20CTLA4\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229e4959f6f316927771978bb152d440\x22>receptor</span>\x20</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p\x20style=\x22text-align:\x20center;\x22><strong>Blocks\x20PD-L-1\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229e4959f6f316927771978bb152d440\x22>receptor</span>\x20</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p\x20style=\x22text-align:\x20center;\x22><strong>Blocks\x20PD-1\x20receptor</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<ul>\x0a\x09\x09\x09\x09<li>Ipilimumab</li>\x0a\x09\x09\x09\x09<li>Tremelimumab</li>\x0a\x09\x09\x09</ul>\x0a\x09\x09\x09<br\x20/>\x0a\x09\x09\x09\u00a0</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<ul>\x0a\x09\x09\x09\x09<li>Atezolizumab</li>\x0a\x09\x09\x09\x09<li>Avelumab</li>\x0a\x09\x09\x09\x09<li>Durvalumab</li>\x0a\x09\x09\x09</ul>\x0a\x09\x09\x09<br\x20/>\x0a\x09\x09\x09\u00a0</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<ul>\x0a\x09\x09\x09\x09<li>Nivolumab</li>\x0a\x09\x09\x09\x09<li>Cepilimumab</li>\x0a\x09\x09\x09\x09<li>Pembrolizumab</li>\x0a\x09\x09\x09</ul>\x0a\x0a\x09\x09\x09<p>\u00a0</p>\x0a\x0a\x09\x09\x09<p>\u00a0</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09</tbody>\x0a</table>','explanation_audio_eng','video[data-src]','removeItem','explanationVideoPlayer','statsBar','Marginal\x20Zone\x20Lymphoma','OdTog','uobOu','Option\x20','<p><strong>Correct\x20Answer:\x20C)\x20Ripretinib</strong></p>\x0a\x0a<p><strong>Explanation:</strong></p>\x0a\x0a<ul>\x0a\x09<li><strong>Ripretinib</strong>\x20is\x20a\x20<strong>switch-control\x20tyrosine\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229863da498e1692777190e1c6515b48\x22>kinase</span>\x20inhibitor</strong>\x20developed\x20for\x20use\x20in\x20<strong>GIST</strong>,\x20particularly\x20after\x20resistance\x20to\x20other\x20TKIs.<br\x20/>\x0a\x09\u00a0</li>\x0a\x09<li>It\x20selectively\x20targets\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x225663b887111692777193059c055492\x22>mutant</span>\x20forms\x20of\x20<strong>KIT\x20and\x20PDGFRα</strong>,\x20offering\x20improved\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22f03ca2d2a716927771901227bc175a\x22>inhibition</span>\x20of\x20a\x20wide\x20spectrum\x20of\x20mutations,\x20but\x20with\x20more\x20<strong>specificity\x20for\x20PDGFR</strong>\x20compared\x20to\x20multikinase\x20inhibitors\x20like\x20sunitinib\x20and\x20regorafenib.<br\x20/>\x0a\x09\u00a0</li>\x0a\x09<li>It\x20is\x20used\x20as\x20<strong>fourth-line\x20treatment</strong>\x20in\x20GIST\x20after\x20failure\x20of\x20imatinib,\x20sunitinib,\x20and\x20regorafenib.<br\x20/>\x0a\x09\u00a0</li>\x0a</ul>\x0a\x0a<p><strong>GIST\x20treatment\x20and\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229863da498e1692777190e1c6515b48\x22>kinase</span>\x20targets\x20comparison:</strong><br\x20/>\x0a\u00a0</p>\x0a\x0a<table\x20cellspacing=\x220\x22\x20style=\x22border-collapse:collapse;\x20width:624px\x22>\x0a\x09<tbody>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Drug</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Primary\x20Targets</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Line\x20of\x20Therapy\x20in\x20GIST</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Imatinib</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>c-KIT,\x20PDGFRα</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>First-line</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Sunitinib</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Multiple\x20TKs:\x20KIT,\x20PDGFR,\x20VEGFR</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Second-line</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Regorafenib</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Multikinase:\x20KIT,\x20PDGFR,\x20VEGFR,\x20RAF,\x20etc.</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Third-line</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Ripretinib</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Broad-spectrum\x20KIT\x20and\x20PDGFRα\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22f03ca2d2a716927771901227bc175a\x22>inhibition</span>\x20(switch-control)</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Fourth-line\x20or\x20resistant\x20cases</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09</tbody>\x0a</table>\x0a\x0a<p><br\x20/>\x0a\u00a0</p>\x0a\x0a<p><strong>Imatinib\x20(Option\x20A):</strong>\x20Incorrect\x20-\x20though\x20it\x20targets\x20PDGFR,\x20it\x20is\x20not\x20selective\x20and\x20also\x20targets\x20BCR-ABL,\x20KIT,\x20etc.<br\x20/>\x0a\u00a0</p>\x0a\x0a<p><strong>Sunitinib\x20(Option\x20B):</strong>\x20Incorrect\x20-\x20a\x20<strong>broad\x20multikinase\x20inhibitor</strong>,\x20including\x20PDGFR,\x20VEGFR,\x20KIT,\x20FLT3.<br\x20/>\x0a\u00a0</p>\x0a\x0a<p><strong>Regorafenib\x20(Option\x20D):</strong>\x20Incorrect\x20-\x20a\x20<strong>broad-spectrum\x20multikinase\x20inhibitor</strong>\x20with\x20less\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22e70dd3ea9916927771988faba61d64\x22>specificity</span>\x20for\x20PDGFR.</p>\x0a\x0a<p>\u00a0</p>','querySelectorAll','<div\x20class=\x22mt-4\x22><video\x20id=\x22review-video-','puQiV','<p>A\x2060-year-old\x20male\x20with\x20a\x20significant\x20smoking\x20history\x20presents\x20with\x20a\x20persistent\x20cough,\x20dyspnea,\x20weight\x20loss,\x20and\x20fatigue.\x20A\x20Chest\x20CT\x20reveals\x20a\x20suspicious\x20mass\x20in\x20the\x20right\x20upper\x20lobe.\x20A\x20biopsy\x20of\x20the\x20mass\x20shows\x20adenocarcinoma.\x20Further\x20molecular\x20testing\x20reveals\x20high\x20PD-L1\x20expression\x20(>50%)\x20and\x20no\x20actionable\x20mutations\x20in\x20EGFR,\x20ALK,\x20or\x20ROS1.\x20Which\x20of\x20the\x20following\x20drugs\x20would\x20you\x20choose\x20as\x20the\x20first\x20line\x20of\x20treatment\x20in\x20this\x20case?</p>','data-option-index','1-B,\x202-C,\x203-D,\x204-A','modeModal','lerjm','DZZRh','questionIndex','lezFd','nav-btn-answered','Secukinumab','gfaaJ','toISOString','hpXEW'];_0x1d31=function(){return _0x269bcf;};return _0x1d31();}const _0x4999f1=(function(){let _0x555b20=!![];return function(_0x598f32,_0x418607){const _0x3835a5=_0x555b20?function(){if(_0x418607){const _0x21f118=_0x418607['apply'](_0x598f32,arguments);return _0x418607=null,_0x21f118;}}:function(){};return _0x555b20=![],_0x3835a5;};}()),_0x52957a=_0x4999f1(this,function(){const _0x3222e5=_0x2020,_0x5eda05={'lQkLp':function(_0x203c0c){return _0x203c0c();},'dgEYs':function(_0x2f6271,_0x12f7db){return _0x2f6271===_0x12f7db;},'TxOGo':_0x3222e5(0xff),'lezFd':_0x3222e5(0x2d3),'kSiNP':_0x3222e5(0x28f),'Pehgj':_0x3222e5(0xd5),'cAghe':function(_0x300d11,_0x2d62db){return _0x300d11(_0x2d62db);},'UHjmD':function(_0xda63c,_0x37d139){return _0xda63c+_0x37d139;},'UPnTd':function(_0x17a0c1,_0x391d15){return _0x17a0c1!==_0x391d15;},'xVRVX':_0x3222e5(0x2aa),'TrSDD':_0x3222e5(0x34c),'qTpaP':_0x3222e5(0x1ac),'djpqS':_0x3222e5(0x27e),'KDaeW':'info','JRHMK':_0x3222e5(0x306),'IRaZp':_0x3222e5(0x2d9),'PRSfM':_0x3222e5(0x257),'MnXHq':function(_0x564207,_0x11163c){return _0x564207<_0x11163c;}};let _0xa8cdda;try{if(_0x5eda05[_0x3222e5(0x251)](_0x5eda05[_0x3222e5(0x1be)],_0x5eda05['Pehgj'])){const _0xbd2b8d=_0x5eda05[_0x3222e5(0x158)](Function,_0x5eda05[_0x3222e5(0xd6)](_0x3222e5(0x1b9),'{}.constructor(\x22return\x20this\x22)(\x20)')+');');_0xa8cdda=_0x5eda05[_0x3222e5(0x321)](_0xbd2b8d);}else{if(!_0x5e8582)_0x5eda05[_0x3222e5(0x321)](_0x158d89);_0x49986e['location']['href']=_0x4b9b96[_0x3222e5(0x208)]||_0x3222e5(0x14e);}}catch(_0x341f2a){if(_0x5eda05[_0x3222e5(0x313)](_0x5eda05[_0x3222e5(0x332)],_0x5eda05[_0x3222e5(0x12d)]))_0xa8cdda=window;else{const _0x4169a4=_0x293a6f[_0x3222e5(0x1d2)][_0x331b72[_0x3222e5(0x285)]];_0x5eda05[_0x3222e5(0x251)](_0x4169a4['id'],_0x1a8132)?(_0x1d820d=_0x3222e5(0x190),_0x47fc40=_0x5eda05['TxOGo']):(_0x55a9fa=_0x5eda05[_0x3222e5(0x1ec)],_0xd26a91=_0x5eda05[_0x3222e5(0x153)]);}}const _0x313a73=_0xa8cdda[_0x3222e5(0x11b)]=_0xa8cdda[_0x3222e5(0x11b)]||{},_0x1d6c66=[_0x5eda05[_0x3222e5(0x282)],_0x5eda05[_0x3222e5(0x2df)],_0x5eda05[_0x3222e5(0x2d6)],_0x5eda05[_0x3222e5(0x22c)],'exception',_0x5eda05['IRaZp'],_0x5eda05[_0x3222e5(0xdf)]];for(let _0x3d6226=0x0;_0x5eda05['MnXHq'](_0x3d6226,_0x1d6c66[_0x3222e5(0x303)]);_0x3d6226++){const _0x52afeb=_0x4999f1[_0x3222e5(0x101)][_0x3222e5(0x136)][_0x3222e5(0x19a)](_0x4999f1),_0x481d64=_0x1d6c66[_0x3d6226],_0x11980c=_0x313a73[_0x481d64]||_0x52afeb;_0x52afeb[_0x3222e5(0x113)]=_0x4999f1[_0x3222e5(0x19a)](_0x4999f1),_0x52afeb[_0x3222e5(0x132)]=_0x11980c[_0x3222e5(0x132)][_0x3222e5(0x19a)](_0x11980c),_0x313a73[_0x481d64]=_0x52afeb;}});_0x52957a();let questionsData=[{'text':_0x3e8868(0x33a),'choices':[{'id':0x1,'text':_0x3e8868(0x2c1)},{'id':0x2,'text':_0x3e8868(0xeb)},{'id':0x3,'text':_0x3e8868(0x140)},{'id':0x4,'text':_0x3e8868(0x2e5)}],'correct_choice_id':0x2,'solution':_0x3e8868(0x2b1),'question_images':[],'explanation_video':null,'explanation_images':[],'explanation_audio_eng':_0x3e8868(0x2c5),'explanation_audio_hin':_0x3e8868(0x1c6)},{'text':'<p>A\x2060-year-old\x20female\x20patient\x20diagnosed\x20with\x20a\x20gastrointestinal\x20stromal\x20tumor\x20(GIST)\x20has\x20been\x20started\x20on\x20first-line\x20treatment.\x20Genetic\x20testing\x20reveals\x20a\x20mutation\x20in\x20the\x20c-KIT\x20gene.\x20After\x20several\x20months,\x20the\x20patient\x20develops\x20resistance\x20to\x20the\x20initial\x20therapy.\x20The\x20oncologist\x20considers\x20alternative\x20medications.\x20Which\x20of\x20the\x20following\x20drugs\x20is\x20specifically\x20known\x20for\x20selectively\x20inhibiting\x20the\x20Platelet-Derived\x20Growth\x20Factor\x20Receptor\x20(PDGFR)\x20rather\x20than\x20multiple\x20tyrosine\x20kinase\x20receptors?</p>','choices':[{'id':0x1,'text':_0x3e8868(0xeb)},{'id':0x2,'text':'Sunitinib'},{'id':0x3,'text':'Ripretinib'},{'id':0x4,'text':'Regorafenib'}],'correct_choice_id':0x3,'solution':_0x3e8868(0x1e1),'question_images':[],'explanation_video':null,'explanation_images':[],'explanation_audio_eng':'https://image.prepladder.com/content/PjyAPnu9vpOR3j6ASqrB1748866483.mp3','explanation_audio_hin':_0x3e8868(0x100)},{'text':_0x3e8868(0x33b),'choices':[{'id':0x1,'text':_0x3e8868(0x378)},{'id':0x2,'text':_0x3e8868(0x1dd)},{'id':0x3,'text':_0x3e8868(0x345)},{'id':0x4,'text':_0x3e8868(0x20b)}],'correct_choice_id':0x4,'solution':_0x3e8868(0x241),'question_images':[],'explanation_video':null,'explanation_images':[],'explanation_audio_eng':_0x3e8868(0x166),'explanation_audio_hin':_0x3e8868(0x249)},{'text':_0x3e8868(0x2ab),'choices':[{'id':0x1,'text':_0x3e8868(0x26a)},{'id':0x2,'text':_0x3e8868(0x19e)},{'id':0x3,'text':_0x3e8868(0x347)},{'id':0x4,'text':_0x3e8868(0x1e7)}],'correct_choice_id':0x4,'solution':'<p><strong>Correct\x20Answer</strong>:\x20<strong>D)\u00a01-B,\x202-C,\x203-D,\x204-A</strong></p>\x0a\x0a<p><strong>Explanation:</strong></p>\x0a\x0a<table\x20cellspacing=\x220\x22\x20style=\x22border-collapse:collapse;\x20width:624px\x22>\x0a\x09<tbody>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Drug</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Matched\x20Target</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Mechanism\x20&\x20Clinical\x20Use</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Erlotinib</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>B.\x20HER1\x20(EGFR)\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x227a67bdf6f81692777193cfd480f228\x22>mutation</span>\x20in\x20NSCLC</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Reversible\x20tyrosine\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229863da498e1692777190e1c6515b48\x22>kinase</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22b5fb56a28b1692777190396ae8b625\x22>inhibitor</span>\x20(TKI)\x20of\x20<strong>EGFR\x20(HER1)</strong>;\x20used\x20in\x20<strong>EGFR-mutant\x20NSCLC</strong>.</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Osimertinib</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>C.\x20T790M\x20EGFR\x20mutation</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>3rd-generation\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22ee77d507701692777190bfcf47b497\x22>irreversible</span>\x20EGFR-TKI\x20that\x20targets\x20<strong>T790M</strong>,\x20a\x20common\x20resistance\x20mutation.</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Lapatinib</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>A.\x20HER2\x20(+)ve\x20Breast\x20Cancer</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Dual\x20<strong>HER2\x20and\x20EGFR</strong>\x20TKI\x20used\x20for\x20<strong>HER2-positive\x20breast\x20cancer</strong>,\x20usually\x20after\x20trastuzumab.</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Neratinib</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>D.\x20Trastuzumab-resistant\x20HER2+\x20Cancer</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Irreversible\x20pan-HER\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22b5fb56a28b1692777190396ae8b625\x22>inhibitor</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22e4865847fa169277720044d7b530b0\x22>targeting</span>\x20<strong>HER1,\x20HER2,\x20and\x20HER4</strong>,\x20effective\x20after\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x223c1f84a831169277720091463322a7\x22>trastuzumab</span>\x20failure.</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09</tbody>\x0a</table>\x0a\x0a<p>\u00a0</p>\x0a\x0a<h3><strong>Targeted\x20Therapy\x20in\x20Oncology</strong></h3>\x0a\x0a<table\x20cellspacing=\x220\x22\x20style=\x22border-collapse:collapse;\x20width:624px\x22>\x0a\x09<tbody>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Target</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Common\x20Mutation/Context</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Targeted\x20Drugs</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>EGFR\x20(HER1)</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>NSCLC\x20with\x20EGFR\x20mutations</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Erlotinib,\x20Gefitinib,\x20Afatinib</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>T790M\x20mutation</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Resistance\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x227a67bdf6f81692777193cfd480f228\x22>mutation</span>\x20in\x20EGFR+\x20NSCLC</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Osimertinib</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>HER2</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>HER2-positive\x20breast\x20cancer</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Trastuzumab,\x20Pertuzumab,\x20Lapatinib,\x20Neratinib</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Trastuzumab-resistance</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>HER2+\x20breast\x20cancer\x20non-responsive\x20to\x20trastuzumab</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Neratinib,\x20Tucatinib</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09</tbody>\x0a</table>\x0a\x0a<p>\u00a0</p>','question_images':[],'explanation_video':null,'explanation_images':[],'explanation_audio_eng':'https://image.prepladder.com/content/luCUITBGFj6QRRmxOs2S1746256860.mp3','explanation_audio_hin':_0x3e8868(0x1a1)},{'text':_0x3e8868(0x15b),'choices':[{'id':0x1,'text':_0x3e8868(0x20e)},{'id':0x2,'text':'1-D,\x202-C,\x203-A,\x204-B'},{'id':0x3,'text':_0x3e8868(0x2de)},{'id':0x4,'text':_0x3e8868(0xd8)}],'correct_choice_id':0x1,'solution':'<p><strong>Correct\x20Answer:\x20A)\x201-D,\x202-C,\x203-B,\x204-A</strong></p>\x0a\x0a<p><strong>Explanation:</strong></p>\x0a\x0a<ul>\x0a\x09<li><strong>Pazopanib\x20-</strong>\x20VEGFR\x20Inhibitor-\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22b9356afdba16927771979d068c6587\x22>Renal</span>\x20Cell\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22988c19e3131692777183b6744d1920\x22>Carcinoma</span>\x20(RCC)</li>\x0a\x09<li><strong>Midostaurin\x20-\x20</strong>VEGFR\x20Inhibitor-\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x224cdc8161f71692777180df58cafa93\x22>Acute</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22da88d7f2211692777193037caba514\x22>Myeloid</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x224521dbf4b91692777191a73002bf98\x22>Leukemia</span>\x20(AML)\x20with\x20FLT-3\x20mutation</li>\x0a\x09<li><strong>Erdafitinib\x20</strong>-\x20FGFR\x20Inhibitor-\x20Urothelial\x20Carcinoma</li>\x0a\x09<li><strong>Infigratinib\x20-</strong>\x20FGFR\x20Inhibitor-\x20Cholangiocarcinoma</li>\x0a</ul>\x0a\x0a<p><strong>VEGFR\x20Inhibitors\x20and\x20uses:</strong></p>\x0a\x0a<table\x20cellspacing=\x220\x22\x20style=\x22width:624px\x22>\x0a\x09<tbody>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-color:#000000;\x20border-style:solid\x22>\x0a\x09\x09\x09<p><strong>Drug\x20Name</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-color:#000000;\x20border-style:solid\x22>\x0a\x09\x09\x09<p><strong>Clinical\x20Use</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-color:#000000;\x20border-style:solid\x22>\x0a\x09\x09\x09<p>Pazopanib,\x20Axitinib,\x20Tivozanib</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-color:#000000;\x20border-style:solid\x22>\x0a\x09\x09\x09<p>Renal\x20Cell\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22988c19e3131692777183b6744d1920\x22>Carcinoma</span>\x20(RCC)</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-color:#000000;\x20border-style:solid\x22>\x0a\x09\x09\x09<p>Sorafenib,\x20Lenvatinib</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-color:#000000;\x20border-style:solid\x22>\x0a\x09\x09\x09<p>Renal\x20Cell\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22988c19e3131692777183b6744d1920\x22>Carcinoma</span>\x20(RCC),\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x226165f47a8c1692777188c0dfc0d75d\x22>Hepatocellular</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22988c19e3131692777183b6744d1920\x22>Carcinoma</span>\x20(HCC)</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-color:#000000;\x20border-style:solid\x22>\x0a\x09\x09\x09<p>Sunitinib,\x20Regorafenib</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-color:#000000;\x20border-style:solid\x22>\x0a\x09\x09\x09<p>Renal\x20Cell\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22988c19e3131692777183b6744d1920\x22>Carcinoma</span>\x20(RCC),\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22b3a647ce2516927771881427f56c1d\x22>Gastrointestinal</span>\x20Stromal\x20Tumors\x20(GIST)</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-color:#000000;\x20border-style:solid\x22>\x0a\x09\x09\x09<p>Vandetanib,\x20Cabozantinib</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-color:#000000;\x20border-style:solid\x22>\x0a\x09\x09\x09<p>Medullary\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22988c19e3131692777183b6744d1920\x22>Carcinoma</span>\x20of\x20the\x20Thyroid</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-color:#000000;\x20border-style:solid\x22>\x0a\x09\x09\x09<p>Midostaurin,\x20Gilteritinib</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-color:#000000;\x20border-style:solid\x22>\x0a\x09\x09\x09<p>Acute\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22da88d7f2211692777193037caba514\x22>Myeloid</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x224521dbf4b91692777191a73002bf98\x22>Leukemia</span>\x20(AML)\x20with\x20FLT-3\x20mutation</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09</tbody>\x0a</table>\x0a\x0a<p><strong>FGFR\x20Inhibitors\x20and\x20uses:</strong></p>\x0a\x0a<table\x20cellspacing=\x220\x22\x20style=\x22border-collapse:collapse;\x20width:624px\x22>\x0a\x09<tbody>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Drug\x20Name</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p><strong>Clinical\x20Use</strong></p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Erdafitinib</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Urothelial\x20Carcinoma</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09\x09<tr>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Pemigatinib,\x20Infigratinib</p>\x0a\x09\x09\x09</td>\x0a\x09\x09\x09<td\x20style=\x22border-bottom:1px\x20solid\x20#000000;\x20border-left:1px\x20solid\x20#000000;\x20border-right:1px\x20solid\x20#000000;\x20border-top:1px\x20solid\x20#000000;\x20vertical-align:top\x22>\x0a\x09\x09\x09<p>Cholangiocarcinoma</p>\x0a\x09\x09\x09</td>\x0a\x09\x09</tr>\x0a\x09</tbody>\x0a</table>\x0a\x0a<p>\u00a0</p>\x0a\x0a<p>\u00a0</p>\x0a\x0a<p>\u00a0</p>','question_images':[],'explanation_video':null,'explanation_images':[],'explanation_audio_eng':_0x3e8868(0x1fb),'explanation_audio_hin':'https://image.prepladder.com/content/W6FZnYbZmxb7EZQ9aNQr1749201642.mp3'},{'text':_0x3e8868(0x275),'choices':[{'id':0x1,'text':_0x3e8868(0x349)},{'id':0x2,'text':'Binimetinib'},{'id':0x3,'text':_0x3e8868(0x312)},{'id':0x4,'text':_0x3e8868(0x168)}],'correct_choice_id':0x2,'solution':_0x3e8868(0x179),'question_images':[],'explanation_video':null,'explanation_images':[],'explanation_audio_eng':_0x3e8868(0x22a),'explanation_audio_hin':_0x3e8868(0x135)},{'text':_0x3e8868(0x146),'choices':[{'id':0x1,'text':_0x3e8868(0x287)},{'id':0x2,'text':_0x3e8868(0x114)},{'id':0x3,'text':'Trastuzumab'},{'id':0x4,'text':_0x3e8868(0x276)}],'correct_choice_id':0x3,'solution':_0x3e8868(0x230),'question_images':[],'explanation_video':null,'explanation_images':[_0x3e8868(0x323)],'explanation_audio_eng':_0x3e8868(0xfb),'explanation_audio_hin':_0x3e8868(0x189)},{'text':_0x3e8868(0x1e5),'choices':[{'id':0x1,'text':'Erlotinib'},{'id':0x2,'text':_0x3e8868(0x276)},{'id':0x3,'text':_0x3e8868(0x1b7)},{'id':0x4,'text':'Ipilimumab'}],'correct_choice_id':0x3,'solution':_0x3e8868(0x1d7),'question_images':[],'explanation_video':null,'explanation_images':[_0x3e8868(0x22e)],'explanation_audio_eng':'https://image.prepladder.com/content/QEday2gHpta3zqV73ZZB1749204044.mp3','explanation_audio_hin':_0x3e8868(0x298)},{'text':_0x3e8868(0x2c7),'choices':[{'id':0x1,'text':_0x3e8868(0x29b)},{'id':0x2,'text':_0x3e8868(0x1ee)},{'id':0x3,'text':'Etanercept'},{'id':0x4,'text':'Mogamulizumab'}],'correct_choice_id':0x4,'solution':_0x3e8868(0x18f),'question_images':[],'explanation_video':null,'explanation_images':['https://image.prepladder.com/content/UxLbMXCiokQFduwWthCp1736435945.png'],'explanation_audio_eng':'https://image.prepladder.com/content/K5dZEV9Xo8Y1CkIJjedH1749204195.mp3','explanation_audio_hin':_0x3e8868(0x10c)},{'text':_0x3e8868(0x1cb),'choices':[{'id':0x1,'text':_0x3e8868(0x2a3)},{'id':0x2,'text':_0x3e8868(0x18e)},{'id':0x3,'text':_0x3e8868(0x1ca)},{'id':0x4,'text':'Direct\x20cytotoxicity\x20against\x20tumor\x20cells'}],'correct_choice_id':0x2,'solution':_0x3e8868(0x13e),'question_images':[],'explanation_video':null,'explanation_images':[],'explanation_audio_eng':'https://image.prepladder.com/content/uzMvX5AebGCwqNMXeeuV1749204331.mp3','explanation_audio_hin':_0x3e8868(0x2b2)},{'text':_0x3e8868(0x2d2),'choices':[{'id':0x1,'text':_0x3e8868(0x32a)},{'id':0x2,'text':_0x3e8868(0x1ad)},{'id':0x3,'text':_0x3e8868(0x2e6)},{'id':0x4,'text':'Ixekizumab'}],'correct_choice_id':0x3,'solution':_0x3e8868(0x2ed),'question_images':[],'explanation_video':null,'explanation_images':[],'explanation_audio_eng':_0x3e8868(0x356),'explanation_audio_hin':_0x3e8868(0x2fa)},{'text':_0x3e8868(0x264),'choices':[{'id':0x1,'text':_0x3e8868(0x112)},{'id':0x2,'text':_0x3e8868(0x184)},{'id':0x3,'text':_0x3e8868(0x2f6)},{'id':0x4,'text':_0x3e8868(0x1ba)}],'correct_choice_id':0x4,'solution':_0x3e8868(0x164),'question_images':[],'explanation_video':null,'explanation_images':[],'explanation_audio_eng':_0x3e8868(0xe3),'explanation_audio_hin':_0x3e8868(0x115)},{'text':_0x3e8868(0x24f),'choices':[{'id':0x1,'text':_0x3e8868(0x17e)},{'id':0x2,'text':_0x3e8868(0xe2)},{'id':0x3,'text':'Cetuximab'},{'id':0x4,'text':_0x3e8868(0x276)}],'correct_choice_id':0x2,'solution':'<p><strong>Correct\x20Answer:\x20B)\x20Trastuzumab</strong></p>\x0a\x0a<p><br\x20/>\x0a<strong>Explanation:\x20</strong></p>\x0a\x0a<p>Trastuzumab\x20is\x20a\x20humanized\x20IgG1\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22b2b82438d6169277719287eb450079\x22>monoclonal</span>\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x229d7a12cab116927771811a0079086d\x22>antibody</span>\x20that\x20binds\x20to\x20the\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22ba366417791692777187229d34e597\x22>extracellular</span>\x20domain\x20IV\x20of\x20HER2,\x20reduces\x20HER2\x20signaling,\x20and\x20can\x20induce\x20antibody-dependent,\x20immune\x20cell–mediated\x20cytotoxicity.</p>\x0a\x0a<p><br\x20/>\x0a<strong>Mechanism\x20of\x20action:\x20</strong>Blocks\x20HER2/Neu\x20receptor</p>\x0a\x0a<p><img\x20alt=\x22\x22\x20data-author=\x22\x22\x20data-hash=\x22\x22\x20data-license=\x22\x22\x20data-source=\x22\x22\x20data-tags=\x22\x22\x20height=\x221032\x22\x20src=\x22https://image.prepladder.com/content/VvBJg36GLVy5qZ4ihGbw1736436022.png\x22\x20width=\x221969\x22\x20/></p>\x0a\x0a<p><strong>Therapeutic\x20Uses:</strong></p>\x0a\x0a<ul>\x0a\x09<li>Trastuzumab\x20is\x20approved\x20for\x20HER2-overexpressing\x20breast\x20and\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x2212347b15191692777188bc86d226e1\x22>gastric</span>\x20cancer.</li>\x0a\x09<li>It\x20is\x20used\x20in\x20combination\x20with\x20cytotoxic\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22721ab08250169277718402cade7633\x22>chemotherapeutics</span>\x20such\x20as\x20taxanes\x20as\x20initial\x20treatment\x20or\x20as\x20a\x20single\x20agent\x20following\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22b4b361c37616927771979541177070\x22>relapse</span>\x20of\x20disease\x20after\x20cytotoxic\x20chemotherapy.</li>\x0a</ul>\x0a\x0a<p><strong>Side\x20effects\x20of\x20Trastuzumab:</strong></p>\x0a\x0a<ul>\x0a\x09<li>Cardiotoxic</li>\x0a\x09<li>Should\x20be\x20avoided\x20with\x20<span\x20class=\x22customMeta\x22\x20data-dictid=\x22845ffca50f1692777186d5ed72e81a\x22>Doxorubicin</span>\x20(>30%)</li>\x0a</ul>','question_images':[],'explanation_video':null,'explanation_images':['https://image.prepladder.com/content/VvBJg36GLVy5qZ4ihGbw1736436022.png'],'explanation_audio_eng':_0x3e8868(0xfe),'explanation_audio_hin':_0x3e8868(0x17a)}],quizName=_0x3e8868(0x103);const quizFilename='54-targeted-therapy-and-monoclonal-antibodies-25a0997e.html';let hierarchy=[_0x3e8868(0x28a),_0x3e8868(0x2fb),_0x3e8868(0x26d)];if(window[_0x3e8868(0x194)]['pathname']['endsWith'](_0x3e8868(0xea))){const customData=JSON['parse'](localStorage[_0x3e8868(0x31c)]('customQuizData'));if(customData){const fDofng=_0x3e8868(0x2db)[_0x3e8868(0x1b4)]('|');let MIezHp=0x0;while(!![]){switch(fDofng[MIezHp++]){case'0':questionsData=customData[_0x3e8868(0x1d1)];continue;case'1':hierarchy=customData['hierarchy'];continue;case'2':document[_0x3e8868(0x2ec)]=quizName+_0x3e8868(0x23d);continue;case'3':quizName=customData[_0x3e8868(0x25d)];continue;case'4':document[_0x3e8868(0x2d4)](_0x3e8868(0x1ff))['textContent']=hierarchy[_0x3e8868(0x369)](_0x3e8868(0x274));continue;case'5':document[_0x3e8868(0x2d4)](_0x3e8868(0x2af))[_0x3e8868(0x322)]=questionsData[_0x3e8868(0x303)];continue;}break;}}}let currentQuestionIndex=0x0,selectedOption=null,currentMode=_0x3e8868(0x352),timer=null,timeRemaining=0x0,questionStartTime=Date[_0x3e8868(0xf7)](),quizStartTime=Date[_0x3e8868(0xf7)](),isQuizCompleted=![],questionStates=new Array(questionsData[_0x3e8868(0x303)])[_0x3e8868(0x2a9)](null)[_0x3e8868(0x197)](()=>({'status':'not_attempted','bookmarked':![],'markedForReview':![],'selectedAnswer':null,'timeSpent':0x0})),stats={'correctAnswers':0x0,'incorrectAnswers':0x0,'totalAttempted':0x0,'totalTime':0x0,'notAttempted':questionsData['length']};function saveProgress(){const _0x2d938b=_0x3e8868,_0x21038f={'LUdLM':'userHistory','iYZVC':_0x2d938b(0x23f)};if(isQuizCompleted)return;const _0xa130f4=JSON['parse'](localStorage[_0x2d938b(0x31c)](_0x21038f[_0x2d938b(0x375)]))||{};_0xa130f4[quizFilename]={'questionStates':questionStates,'stats':stats,'currentQuestionIndex':currentQuestionIndex,'currentMode':currentMode,'status':_0x21038f[_0x2d938b(0x104)],'lastSeen':new Date()['toISOString']()},localStorage[_0x2d938b(0xfc)](_0x21038f['LUdLM'],JSON[_0x2d938b(0x328)](_0xa130f4));}function loadProgress(){const _0x14b948=_0x3e8868,_0x5707cf={'OXmFR':_0x14b948(0x26e),'NpyWi':'3|2|0|1|5|4'},_0x521ec0=JSON[_0x14b948(0x307)](localStorage['getItem'](_0x5707cf[_0x14b948(0x10b)]))||{},_0x2cd425=_0x521ec0[quizFilename];if(_0x2cd425){const _0x1fc30c=_0x5707cf[_0x14b948(0x10e)][_0x14b948(0x1b4)]('|');let _0x214d82=0x0;while(!![]){switch(_0x1fc30c[_0x214d82++]){case'0':currentQuestionIndex=_0x2cd425[_0x14b948(0xf6)];continue;case'1':currentMode=_0x2cd425[_0x14b948(0x288)];continue;case'2':stats=_0x2cd425[_0x14b948(0x2f2)];continue;case'3':questionStates=_0x2cd425[_0x14b948(0x362)];continue;case'4':return!![];case'5':console[_0x14b948(0x1ac)]('Progress\x20loaded.');continue;}break;}}return![];}function clearProgress(){const _0x5b68d5=_0x3e8868,_0x1d855d={'OSnTx':_0x5b68d5(0x26e),'FWpDo':_0x5b68d5(0x150)},_0x193475=JSON[_0x5b68d5(0x307)](localStorage['getItem'](_0x5b68d5(0x26e)))||{};_0x193475[quizFilename]&&(delete _0x193475[quizFilename],localStorage[_0x5b68d5(0xfc)](_0x1d855d[_0x5b68d5(0x2fd)],JSON[_0x5b68d5(0x328)](_0x193475)),console[_0x5b68d5(0x1ac)](_0x1d855d[_0x5b68d5(0xec)]));}function markQuizAsCompleted(){const _0x4defd4=_0x3e8868,_0x1e8bd2={'TaxXC':_0x4defd4(0x26e),'zawmh':_0x4defd4(0x17c)},_0x5b2699=JSON[_0x4defd4(0x307)](localStorage[_0x4defd4(0x31c)](_0x1e8bd2[_0x4defd4(0x234)]))||{},_0x14db43=questionsData[_0x4defd4(0x303)],_0x1664cb=stats[_0x4defd4(0x233)]||0x0;_0x5b2699[quizFilename]={'score':_0x1664cb,'total':_0x14db43,'status':_0x1e8bd2['zawmh'],'completedOn':new Date()['toISOString']()},localStorage[_0x4defd4(0xfc)](_0x1e8bd2[_0x4defd4(0x234)],JSON[_0x4defd4(0x328)](_0x5b2699));}const urlParams=new URLSearchParams(window[_0x3e8868(0x194)][_0x3e8868(0x11e)]),startAt=parseInt(urlParams[_0x3e8868(0x243)](_0x3e8868(0x2fe))),resume=urlParams[_0x3e8868(0x243)]('resume')===_0x3e8868(0x2a8);function goBack(){const _0x2b8996=_0x3e8868,_0x1cdb37={'MHRyH':function(_0x47941a){return _0x47941a();},'vwEGH':_0x2b8996(0x14e)};if(!isQuizCompleted)_0x1cdb37[_0x2b8996(0x108)](saveProgress);window[_0x2b8996(0x194)][_0x2b8996(0x2b5)]=document[_0x2b8996(0x208)]||_0x1cdb37[_0x2b8996(0x367)];}function selectMode(_0x1b4dfa){const _0x4d89f0=_0x3e8868,_0x473b37={'ayfpQ':'modeModal'};currentMode=_0x1b4dfa,document[_0x4d89f0(0x2d4)](_0x473b37['ayfpQ'])[_0x4d89f0(0x1b1)][_0x4d89f0(0x302)]=_0x4d89f0(0x301),initializeQuiz();}function initializeQuiz(){const _0xc24087=_0x3e8868,_0x5a5054={'YKyVN':'bookmarkBtn','mSeiW':'testModeReviewLegend','YDYRF':function(_0x52ffaf,_0x1cec2e){return _0x52ffaf===_0x1cec2e;},'iGBNX':_0xc24087(0x36e),'XakRO':function(_0x2bb3cb,_0x3a0c20){return _0x2bb3cb===_0x3a0c20;},'azrFn':'timed_exam','ZUByO':_0xc24087(0x1dc),'SfTLQ':_0xc24087(0x301),'fhLNb':_0xc24087(0xe5),'wEKYO':'flex','FsfTd':_0xc24087(0x1b2),'SBFzb':_0xc24087(0x1ae),'Ylbcq':function(_0x560c0a,_0x5b7e5a){return _0x560c0a(_0x5b7e5a);},'DgJFd':function(_0x4bb834,_0x2aff8f){return _0x4bb834>=_0x2aff8f;},'fRvEa':function(_0x529e18,_0x8afb55){return _0x529e18<_0x8afb55;},'gpPPK':function(_0x3f67ca){return _0x3f67ca();},'aVsEW':function(_0x511a49){return _0x511a49();},'hUCJm':function(_0x131052){return _0x131052();}};quizStartTime=Date[_0xc24087(0xf7)]();const _0x1d51c8=document['getElementById'](_0x5a5054[_0xc24087(0x324)]),_0x8afc08=document[_0xc24087(0x2d4)](_0xc24087(0x1d3)),_0xa54435=document[_0xc24087(0x2d4)](_0x5a5054['mSeiW']),_0x3c87ab=_0x5a5054[_0xc24087(0x267)](currentMode,_0x5a5054[_0xc24087(0x31f)])||_0x5a5054[_0xc24087(0x265)](currentMode,_0x5a5054[_0xc24087(0x1b5)]);document[_0xc24087(0x2d4)](_0x5a5054[_0xc24087(0x2f1)])['style']['display']=_0x3c87ab?_0x5a5054[_0xc24087(0x14d)]:_0xc24087(0xe5),document['getElementById'](_0xc24087(0x2cf))['style']['display']=_0x3c87ab?_0x5a5054['SfTLQ']:_0x5a5054['fhLNb'],document[_0xc24087(0x2d4)]('testModeLegend')[_0xc24087(0x1b1)][_0xc24087(0x302)]=_0x3c87ab?_0x5a5054['fhLNb']:_0xc24087(0x301),document[_0xc24087(0x2d4)]('submitSection')[_0xc24087(0x1b1)][_0xc24087(0x302)]=_0x3c87ab?_0x5a5054[_0xc24087(0x24e)]:_0x5a5054['SfTLQ'],_0x1d51c8[_0xc24087(0x1b1)]['display']=_0x3c87ab?_0x5a5054[_0xc24087(0x14d)]:_0x5a5054[_0xc24087(0x110)],_0x8afc08[_0xc24087(0x1b1)][_0xc24087(0x302)]=_0x3c87ab?_0x5a5054['wEKYO']:_0x5a5054[_0xc24087(0x14d)],_0xa54435[_0xc24087(0x1b1)]['display']=_0x3c87ab?_0x5a5054[_0xc24087(0x110)]:'none',(currentMode===_0x5a5054[_0xc24087(0x236)]||_0x5a5054[_0xc24087(0x265)](currentMode,_0x5a5054[_0xc24087(0x1b5)]))&&document[_0xc24087(0x2d4)]('timerContainer')[_0xc24087(0x2dc)][_0xc24087(0x1a7)](_0x5a5054[_0xc24087(0x263)]),!_0x5a5054[_0xc24087(0x348)](isNaN,startAt)&&_0x5a5054['DgJFd'](startAt,0x0)&&_0x5a5054[_0xc24087(0x205)](startAt,questionsData[_0xc24087(0x303)])&&(currentQuestionIndex=startAt),_0x5a5054[_0xc24087(0x1d4)](loadBookmarkedQuestions),_0x5a5054[_0xc24087(0x246)](generateQuestionNav),updateStats(),_0x5a5054[_0xc24087(0x2a6)](displayQuestion);}function generateQuestionNav(){const _0x3e905a=_0x3e8868,_0x175b67={'oofAD':function(_0x11b2e8,_0x4ea0ee){return _0x11b2e8<_0x4ea0ee;},'rHonh':function(_0xb9a8d5,_0x41f716){return _0xb9a8d5+_0x41f716;},'bscyN':_0x3e905a(0x2e8),'mAhbp':function(_0x239f4f){return _0x239f4f();}},_0x4c1ccd=document[_0x3e905a(0x2d4)](_0x3e905a(0x16c));_0x4c1ccd['innerHTML']='';for(let _0x4279a7=0x0;_0x175b67['oofAD'](_0x4279a7,questionsData[_0x3e905a(0x303)]);_0x4279a7++){const _0x1542ff=document['createElement'](_0x3e905a(0x1af));_0x1542ff[_0x3e905a(0x322)]=_0x175b67[_0x3e905a(0x291)](_0x4279a7,0x1),_0x1542ff[_0x3e905a(0x272)]=_0x175b67[_0x3e905a(0x36b)],_0x1542ff[_0x3e905a(0x25e)]=()=>jumpToQuestion(_0x4279a7),_0x1542ff['id']=_0x3e905a(0x19b)+_0x4279a7,_0x4c1ccd[_0x3e905a(0x277)](_0x1542ff);}_0x175b67[_0x3e905a(0xe0)](updateQuestionNav);}function updateQuestionNav(){const _0x2b1363=_0x3e8868,_0x143c91={'IoWmq':_0x2b1363(0x2d7),'bGkXQ':function(_0x604f64,_0x4593c9,_0x827902){return _0x604f64(_0x4593c9,_0x827902);},'iOfwI':_0x2b1363(0x1d9),'vfDLk':function(_0x50f02f,_0x262c07){return _0x50f02f===_0x262c07;},'mHycf':function(_0x1e602a,_0x143d4d){return _0x1e602a===_0x143d4d;},'bGESn':'OVipf','wHBkl':'nav-btn-current','bIOaE':'nav-btn-bookmarked','VdNeL':_0x2b1363(0x20c),'HDbdT':_0x2b1363(0x352),'DZAka':function(_0x427b06,_0xb1243f){return _0x427b06===_0xb1243f;},'tBRde':_0x2b1363(0x190),'HwtNY':'nav-btn-correct','XhnBY':function(_0xd04558,_0xd6caa9){return _0xd04558!==_0xd6caa9;},'hvkEy':_0x2b1363(0x1ed),'fXDNC':_0x2b1363(0x122)};for(let _0x112913=0x0;_0x112913<questionsData[_0x2b1363(0x303)];_0x112913++){const _0x5e6df3=document['getElementById'](_0x2b1363(0x19b)+_0x112913),_0xa68880=questionStates[_0x112913];let _0x40ec72='';if(_0x143c91[_0x2b1363(0x2eb)](_0x112913,currentQuestionIndex))_0x143c91[_0x2b1363(0x1a0)](_0x143c91[_0x2b1363(0x2a0)],_0x143c91[_0x2b1363(0x2a0)])?_0x40ec72=_0x143c91[_0x2b1363(0x364)]:_0x5320f5['querySelectorAll'](_0x143c91[_0x2b1363(0x31b)])[_0x2b1363(0x32d)](_0x5759f1=>{const _0x1181c1=_0x2b1363,_0x10e0f7=_0x5759f1[_0x1181c1(0x238)][_0x1181c1(0x12c)];if(_0x10e0f7&&_0x10e0f7[_0x1181c1(0x374)](_0x143c91[_0x1181c1(0x130)]))_0x143c91[_0x1181c1(0x1cc)](_0x5a2c6a,_0x5759f1,_0x10e0f7);else _0x10e0f7&&(_0x5759f1[_0x1181c1(0x12c)]=_0x10e0f7);});else{if(_0xa68880[_0x2b1363(0x225)])_0x40ec72=_0x143c91[_0x2b1363(0x1b0)];else{if(_0xa68880[_0x2b1363(0x116)])_0x40ec72=_0x143c91[_0x2b1363(0x33d)];else{if(_0x143c91[_0x2b1363(0x1a0)](currentMode,_0x143c91[_0x2b1363(0x20d)])||_0x143c91[_0x2b1363(0x292)](currentMode,_0x2b1363(0x1b2))){if(_0x143c91['mHycf'](_0xa68880[_0x2b1363(0x226)],_0x143c91[_0x2b1363(0x1a5)]))_0x40ec72=_0x143c91[_0x2b1363(0x11f)];else{if(_0x143c91['vfDLk'](_0xa68880[_0x2b1363(0x226)],'incorrect'))_0x40ec72=_0x2b1363(0x157);else _0x40ec72='nav-btn-not-attempted\x20hover:bg-white\x20hover:bg-opacity-20';}}else{if(_0x143c91['XhnBY'](_0xa68880[_0x2b1363(0x285)],null))_0x40ec72=_0x143c91[_0x2b1363(0x372)];else _0x40ec72=_0x143c91[_0x2b1363(0x305)];}}}}_0x5e6df3[_0x2b1363(0x272)]=_0x2b1363(0x11a)+_0x40ec72;}}function jumpToQuestion(_0x2a7495){const _0x3250b6=_0x3e8868,_0xd38a83={'KGnsA':function(_0x63aade,_0x2e62a5){return _0x63aade>=_0x2e62a5;},'ZXwXC':function(_0x1ef48c,_0x43c8f3){return _0x1ef48c<_0x43c8f3;},'MhhXS':function(_0x42c7be,_0x351b89){return _0x42c7be-_0x351b89;},'fjZFE':function(_0x49d8d9){return _0x49d8d9();},'hPOxL':function(_0xfc04ea){return _0xfc04ea();}};_0xd38a83['KGnsA'](_0x2a7495,0x0)&&_0xd38a83[_0x3250b6(0x2a1)](_0x2a7495,questionsData['length'])&&(questionStartTime&&(questionStates[currentQuestionIndex][_0x3250b6(0x15f)]+=_0xd38a83['MhhXS'](Date[_0x3250b6(0xf7)](),questionStartTime)),currentQuestionIndex=_0x2a7495,_0xd38a83[_0x3250b6(0x319)](displayQuestion),_0xd38a83[_0x3250b6(0x317)](saveProgress));}function updateStats(){const _0x4ca32e=_0x3e8868,_0x69d233={'bsfhc':function(_0x4449b8,_0x2811b6){return _0x4449b8===_0x2811b6;},'CqrsE':_0x4ca32e(0x1b2),'GEpPq':'correctCount','NPBFm':_0x4ca32e(0x185),'GVdaZ':function(_0x28166d,_0x4c8a0b){return _0x28166d>_0x4c8a0b;},'mNqZi':function(_0xdac0ad,_0x5c52ed){return _0xdac0ad*_0x5c52ed;},'JrJkL':function(_0x2693ae,_0xcfb870){return _0x2693ae/_0xcfb870;},'Oghgm':_0x4ca32e(0x182),'uJnGj':function(_0x3c5ab0,_0x344449){return _0x3c5ab0+_0x344449;},'VGlny':function(_0x9f2953,_0x7a13e0){return _0x9f2953/_0x7a13e0;},'zBkCH':function(_0x1ba7f2,_0x49bb11){return _0x1ba7f2%_0x49bb11;},'IAiNn':'timeSpent','riQgd':function(_0x2f8334,_0x5579ca){return _0x2f8334+_0x5579ca;},'gGFha':function(_0x3b5cef,_0x4a1433){return _0x3b5cef+_0x4a1433;}};if(_0x69d233[_0x4ca32e(0x2b9)](currentMode,'study')||_0x69d233[_0x4ca32e(0x2b9)](currentMode,_0x69d233['CqrsE'])){document[_0x4ca32e(0x2d4)](_0x69d233['GEpPq'])[_0x4ca32e(0x322)]=stats[_0x4ca32e(0x233)],document[_0x4ca32e(0x2d4)](_0x69d233['NPBFm'])['textContent']=stats[_0x4ca32e(0x337)],document[_0x4ca32e(0x2d4)](_0x4ca32e(0x235))['textContent']=stats['totalAttempted'];const _0x2732de=_0x69d233[_0x4ca32e(0x253)](stats['totalAttempted'],0x0)?Math[_0x4ca32e(0x211)](_0x69d233[_0x4ca32e(0x250)](_0x69d233['JrJkL'](stats[_0x4ca32e(0x233)],stats[_0x4ca32e(0x235)]),0x64)):0x0;document[_0x4ca32e(0x2d4)](_0x69d233[_0x4ca32e(0x308)])[_0x4ca32e(0x322)]=_0x69d233[_0x4ca32e(0x34b)](_0x2732de,'%'),stats[_0x4ca32e(0x1c1)]=questionStates['reduce']((_0x293ad4,_0x4e849f)=>_0x293ad4+_0x4e849f[_0x4ca32e(0x15f)],0x0);const _0x24857f=Math[_0x4ca32e(0x335)](stats[_0x4ca32e(0x1c1)]/0x3e8),_0x35ca09=Math[_0x4ca32e(0x335)](_0x69d233[_0x4ca32e(0x19d)](_0x24857f,0x3c)),_0x361aca=_0x69d233[_0x4ca32e(0x27b)](_0x24857f,0x3c);document[_0x4ca32e(0x2d4)](_0x69d233[_0x4ca32e(0x363)])[_0x4ca32e(0x322)]=_0x69d233['riQgd'](_0x69d233[_0x4ca32e(0x34a)](_0x35ca09,':'),_0x361aca[_0x4ca32e(0x132)]()[_0x4ca32e(0x215)](0x2,'0'));}}function _0x2020(_0x4872d2,_0x24c868){const _0x169ec9=_0x1d31();return _0x2020=function(_0x52957a,_0x4999f1){_0x52957a=_0x52957a-0xcc;let _0x2125ad=_0x169ec9[_0x52957a];return _0x2125ad;},_0x2020(_0x4872d2,_0x24c868);}function setupVideo(_0x3b62c3,_0x561772){const _0x1fecac=_0x3e8868,_0x5804c5={'jcuRG':_0x1fecac(0x106)};if(Hls[_0x1fecac(0x279)]()){const _0x48f40d=new Hls();_0x48f40d[_0x1fecac(0x2b4)](_0x561772),_0x48f40d[_0x1fecac(0x2bb)](_0x3b62c3);}else _0x3b62c3[_0x1fecac(0x176)](_0x5804c5['jcuRG'])&&(_0x3b62c3['src']=_0x561772);}function displayQuestion(){const _0x239a46=_0x3e8868,_0x276175={'tCPmp':_0x239a46(0x2d7),'emKIp':function(_0x3dc97c,_0x52a2cd,_0x2a73ec){return _0x3dc97c(_0x52a2cd,_0x2a73ec);},'yoCts':function(_0x4c2dee,_0xfb3e49){return _0x4c2dee===_0xfb3e49;},'LBYvM':function(_0x2fe215,_0x163724){return _0x2fe215===_0x163724;},'zWcRT':'correct','OzqOW':_0x239a46(0x2d3),'EGxCD':function(_0x2cbd99){return _0x2cbd99();},'Gwiga':function(_0x2ff58d,_0x4b1849){return _0x2ff58d(_0x4b1849);},'WhkQx':_0x239a46(0x198),'GYspe':'selected','ctjja':function(_0x21fe1f,_0x37ba6b){return _0x21fe1f+_0x37ba6b;},'GpIoo':_0x239a46(0x1e0),'MNXua':function(_0x560692,_0x5df439){return _0x560692+_0x5df439;},'XKKiM':'.option-button','bpoWf':_0x239a46(0x31a),'onSZF':_0x239a46(0x11c),'akQzE':_0x239a46(0x271),'zdIKU':function(_0x1fcd6e,_0x29c515){return _0x1fcd6e*_0x29c515;},'mSsgz':function(_0x29d80a,_0x57e396){return _0x29d80a/_0x57e396;},'vGffi':function(_0x5178bb,_0x386d75){return _0x5178bb+_0x386d75;},'ecZms':_0x239a46(0x29e),'nHydt':_0x239a46(0x370),'PgjCD':function(_0x2c8a14,_0x1003d0){return _0x2c8a14===_0x1003d0;},'UZQOQ':_0x239a46(0x1ae),'FdHKv':function(_0xfabc89,_0x53abeb){return _0xfabc89===_0x53abeb;},'jcBHs':_0x239a46(0x175),'INcbc':_0x239a46(0xfa),'SGpcg':_0x239a46(0x353),'nheEg':function(_0x58dce9){return _0x58dce9();},'oafvF':function(_0x1958b6){return _0x1958b6();},'XuAhS':function(_0x32555e,_0x2ca404){return _0x32555e===_0x2ca404;},'wJKUc':_0x239a46(0x1b2)};if(!questionsData||_0x276175[_0x239a46(0x21d)](questionsData[_0x239a46(0x303)],0x0)){if(_0x276175[_0x239a46(0x2cd)]===_0x276175['onSZF']){_0x39f44e[_0x239a46(0x2dc)][_0x239a46(0x1a7)](_0x239a46(0x1ae));if(_0x10bd72[_0x239a46(0x374)](_0x276175['tCPmp']))_0x276175['emKIp'](_0x18454d,_0x15bade,_0x2ecf6e);else _0x4090dd[_0x239a46(0x12c)]=_0x434cf0;}else{document[_0x239a46(0x2d4)](_0x276175[_0x239a46(0x187)])['innerHTML']=_0x239a46(0x133);return;}};const _0x1f527d=questionsData[currentQuestionIndex];questionStartTime=Date[_0x239a46(0xf7)](),selectedOption=questionStates[currentQuestionIndex]['selectedAnswer'];const _0x32d8b1=_0x276175[_0x239a46(0xe6)](_0x276175[_0x239a46(0x354)](_0x276175[_0x239a46(0x27c)](currentQuestionIndex,0x1),questionsData[_0x239a46(0x303)]),0x64);document[_0x239a46(0x2d4)](_0x276175[_0x239a46(0x2e4)])[_0x239a46(0x1b1)][_0x239a46(0x24b)]=_0x276175[_0x239a46(0x316)](_0x32d8b1,'%'),document['getElementById'](_0x276175[_0x239a46(0x360)])[_0x239a46(0x322)]=_0x276175[_0x239a46(0x27c)](currentQuestionIndex,0x1),_0x276175[_0x239a46(0x169)](updateQuestionNav),document['getElementById'](_0x239a46(0x286))[_0x239a46(0x16b)]=_0x276175[_0x239a46(0x1bf)](currentQuestionIndex,0x0),document[_0x239a46(0x2d4)](_0x239a46(0x2ad))['classList'][_0x239a46(0xe9)](_0x276175['UZQOQ']),document[_0x239a46(0x2d4)](_0x276175[_0x239a46(0x187)])[_0x239a46(0x2a7)]=_0x1f527d[_0x239a46(0x1a2)]||_0x239a46(0x17f);let _0x46dc08='';if(_0x1f527d[_0x239a46(0x270)])_0x46dc08+=_0x239a46(0x13d)+_0x1f527d['question_audio']+_0x239a46(0x36a);if(_0x1f527d[_0x239a46(0x180)])_0x46dc08+=_0x239a46(0x30d)+_0x1f527d[_0x239a46(0x180)]+_0x239a46(0x147);if(_0x1f527d['question_images']){if(_0x276175[_0x239a46(0xe1)](_0x276175[_0x239a46(0x2cc)],_0x276175['jcBHs']))_0x1f527d[_0x239a46(0x28d)][_0x239a46(0x32d)](_0x9e526=>{const _0x166c27=_0x239a46;if(_0x9e526)_0x46dc08+='<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><img\x20src=\x22'+_0x9e526+_0x166c27(0x119);});else{const _0x1f3ad8=_0x233670[_0x4683d2],_0x2b0e73=_0x1f3ad8[_0x239a46(0x25c)];if(_0x276175['yoCts'](_0x6dee6a,null))return;const _0xe53dd1=_0x1f3ad8[_0x239a46(0x1d2)][_0x39e184],_0x125912=_0x276175[_0x239a46(0x232)](_0xe53dd1['id'],_0x2b0e73);if(_0x276175['LBYvM'](_0x482bc3[_0x236224]['status'],_0x239a46(0x1bc))){_0x357071[_0x239a46(0x235)]++,_0xf4c867['notAttempted']--;if(_0x125912)_0x59fb8f[_0x239a46(0x233)]++;else _0x22f18b[_0x239a46(0x337)]++;}_0x59877b[_0x2eba3e]['status']=_0x125912?_0x276175[_0x239a46(0x297)]:_0x276175['OzqOW'],_0x276175['EGxCD'](_0x284947),_0x276175[_0x239a46(0x2f5)](_0x58963a,_0x125912),_0x276175['EGxCD'](_0x37c91d);}}document[_0x239a46(0x2d4)](_0x276175[_0x239a46(0x2ac)])[_0x239a46(0x2a7)]=_0x46dc08;const _0x19ab9a=document[_0x239a46(0x2d4)](_0x276175['SGpcg']);_0x19ab9a[_0x239a46(0x2a7)]='',_0x19ab9a['classList'][_0x239a46(0x1a7)]('answered'),_0x1f527d[_0x239a46(0x1d2)]&&Array[_0x239a46(0x37b)](_0x1f527d[_0x239a46(0x1d2)])&&(_0x1f527d['choices'][_0x239a46(0x32d)]((_0x1d5d08,_0x1376fa)=>{const _0x359fe0=_0x239a46,_0xeaa896=String[_0x359fe0(0x373)](0x41+_0x1376fa),_0x574d88=_0x276175[_0x359fe0(0x21d)](selectedOption,_0x1376fa),_0x351a76=document[_0x359fe0(0x1c7)](_0x276175[_0x359fe0(0x36c)]);_0x351a76[_0x359fe0(0x2a7)]=_0x359fe0(0x1c3)+(_0x574d88?_0x276175[_0x359fe0(0x252)]:'')+'\x22\x20data-option-index=\x22'+_0x1376fa+_0x359fe0(0x280)+_0xeaa896+_0x359fe0(0x152)+(_0x1d5d08['text']||_0x276175[_0x359fe0(0x2cb)](_0x276175['GpIoo'],_0x276175['MNXua'](_0x1376fa,0x1)))+_0x359fe0(0x138),_0x19ab9a[_0x359fe0(0x277)](_0x351a76);}),_0x19ab9a[_0x239a46(0x33f)](_0x239a46(0x1f9),function(_0x2effc4){const _0x482814=_0x239a46,_0x2d1f18=_0x2effc4[_0x482814(0x213)][_0x482814(0x120)](_0x276175[_0x482814(0x16d)]);if(_0x2d1f18){const _0x22d870=_0x276175[_0x482814(0x2f5)](parseInt,_0x2d1f18['getAttribute']('data-option-index'));_0x276175[_0x482814(0x2f5)](selectOption,_0x22d870);}})),_0x276175[_0x239a46(0x255)](updateBookmarkButton),_0x276175[_0x239a46(0x18d)](updateMarkReviewButton),(_0x276175[_0x239a46(0x13f)](currentMode,_0x276175['wJKUc'])||currentMode===_0x239a46(0xda))&&!isQuizCompleted&&startTimer();}function selectOption(_0x37a78c){const _0x610954=_0x3e8868,_0x3c8b29={'cpulB':_0x610954(0x37a),'MkmYV':'incorrectCount','XoDBE':_0x610954(0x235),'aUGKc':function(_0x32db8a,_0x12ce83){return _0x32db8a*_0x12ce83;},'dOfFh':function(_0x3b72f9,_0x3a106e){return _0x3b72f9/_0x3a106e;},'ThLCb':_0x610954(0x182),'GKFSr':function(_0xf9524b,_0x4f5689){return _0xf9524b+_0x4f5689;},'QRwkk':function(_0x3449cf,_0x34bd23){return _0x3449cf%_0x34bd23;},'tSffB':_0x610954(0x15f),'sZvQY':_0x610954(0x2d0),'qpLLE':function(_0x4a7120,_0x4a27eb){return _0x4a7120===_0x4a27eb;},'NppYx':_0x610954(0x109),'KUTzW':function(_0x3827d2){return _0x3827d2();},'MBroU':_0x610954(0x353),'qUvlt':_0x610954(0x346),'vFBGQ':function(_0x9d20f3,_0x2d28be){return _0x9d20f3===_0x2d28be;},'EWOIe':_0x610954(0x315),'irEhg':function(_0x4d6159,_0x234aa2){return _0x4d6159-_0x234aa2;},'RiNQz':_0x610954(0x21b),'xjtzq':function(_0xe70223,_0x4b1c16){return _0xe70223===_0x4b1c16;},'xaykk':'study','yqJbM':_0x610954(0x1b2),'mxRNF':function(_0x99cc00,_0x3412be){return _0x99cc00!==_0x3412be;},'nzRhj':_0x610954(0x343),'UDtCt':'nRCmi','noySN':function(_0x710a15){return _0x710a15();},'Lmfhd':function(_0x59b039,_0x3392c7){return _0x59b039===_0x3392c7;},'mLJkl':'not_attempted','vTmqb':function(_0x27755f){return _0x27755f();},'IBKMr':function(_0x591392){return _0x591392();}},_0x4efb3c=document[_0x610954(0x2d4)](_0x3c8b29['MBroU']);if(_0x4efb3c[_0x610954(0x2dc)][_0x610954(0x2c0)](_0x3c8b29[_0x610954(0x326)]))return;if(questionStartTime){if(_0x3c8b29['vFBGQ'](_0x610954(0x315),_0x3c8b29[_0x610954(0x218)]))questionStates[currentQuestionIndex][_0x610954(0x15f)]+=_0x3c8b29[_0x610954(0x2c9)](Date[_0x610954(0xf7)](),questionStartTime),questionStartTime=Date[_0x610954(0xf7)]();else{_0x4dfea5[_0x610954(0x2d4)](_0x3c8b29['cpulB'])[_0x610954(0x322)]=_0x2987f0[_0x610954(0x233)],_0x11c1e6[_0x610954(0x2d4)](_0x3c8b29[_0x610954(0x223)])[_0x610954(0x322)]=_0xa4c3d0[_0x610954(0x337)],_0x59ea6d[_0x610954(0x2d4)](_0x3c8b29[_0x610954(0x2f0)])[_0x610954(0x322)]=_0x2721f8[_0x610954(0x235)];const _0x46b0e5=_0x495297[_0x610954(0x235)]>0x0?_0x172faa['round'](_0x3c8b29[_0x610954(0xd9)](_0x3c8b29[_0x610954(0x219)](_0x5c5f10[_0x610954(0x233)],_0x272f42[_0x610954(0x235)]),0x64)):0x0;_0x3798d9[_0x610954(0x2d4)](_0x3c8b29['ThLCb'])[_0x610954(0x322)]=_0x3c8b29[_0x610954(0x338)](_0x46b0e5,'%'),_0x1fd5f2[_0x610954(0x1c1)]=_0xd4969e[_0x610954(0x357)]((_0x1e881e,_0x5ad555)=>_0x1e881e+_0x5ad555['timeSpent'],0x0);const _0x34ce06=_0x8ce20f[_0x610954(0x335)](_0x57076a[_0x610954(0x1c1)]/0x3e8),_0x2d9ff8=_0x5ef5b2[_0x610954(0x335)](_0x3c8b29[_0x610954(0x219)](_0x34ce06,0x3c)),_0x365cf9=_0x3c8b29[_0x610954(0x32f)](_0x34ce06,0x3c);_0x5bd574[_0x610954(0x2d4)](_0x3c8b29[_0x610954(0x16a)])[_0x610954(0x322)]=_0x3c8b29[_0x610954(0x338)](_0x2d9ff8+':',_0x365cf9['toString']()[_0x610954(0x215)](0x2,'0'));}}selectedOption=_0x37a78c,questionStates[currentQuestionIndex][_0x610954(0x285)]=_0x37a78c,document[_0x610954(0x1e2)](_0x3c8b29[_0x610954(0x222)])[_0x610954(0x32d)]((_0x57df39,_0x9b92c2)=>{const _0x5781ce=_0x610954;_0x57df39[_0x5781ce(0x2dc)][_0x5781ce(0x15d)](_0x3c8b29[_0x5781ce(0x10d)],_0x3c8b29['qpLLE'](_0x9b92c2,_0x37a78c));});if(_0x3c8b29[_0x610954(0x212)](currentMode,_0x3c8b29[_0x610954(0x125)])||_0x3c8b29[_0x610954(0x377)](currentMode,_0x3c8b29[_0x610954(0x340)])){if(_0x3c8b29['mxRNF'](_0x3c8b29[_0x610954(0x1fc)],_0x3c8b29['UDtCt']))_0x3c8b29['noySN'](processAnswer);else{const _0x23bb34=!_0x186b40[_0x1734dc]['bookmarked'];_0x10c427[_0x1c2758][_0x610954(0x225)]=_0x23bb34;let _0x1da4b3=_0x3bc455[_0x610954(0x307)](_0x15cb14['getItem'](_0x3c8b29[_0x610954(0x29c)]))||[];if(_0x23bb34){const _0xa17435={'quizName':_0x62e488,'quizFile':_0x147172[_0x610954(0x194)][_0x610954(0x2fc)][_0x610954(0x1b4)]('/')[_0x610954(0x2a2)](),'questionIndex':_0x924cb4,'question':_0x5d345b[_0x23618e],'hierarchy':_0x3be562,'timestamp':_0x5ec55b[_0x610954(0xf7)]()};_0x1da4b3[_0x610954(0x210)](_0xa17435);}else _0x1da4b3=_0x1da4b3['filter'](_0x906401=>!(_0x906401[_0x610954(0x161)][_0x610954(0x374)](_0xc7c748['toLowerCase']()[_0x610954(0x1c2)](/ /g,'-'))&&_0x906401['questionIndex']===_0x26c9c2));_0x420af3[_0x610954(0xfc)](_0x3c8b29[_0x610954(0x29c)],_0x5588a9[_0x610954(0x328)](_0x1da4b3)),_0x3c8b29['KUTzW'](_0x1b9701),_0x3954fa();}}else _0x3c8b29[_0x610954(0xf4)](questionStates[currentQuestionIndex]['status'],_0x3c8b29[_0x610954(0x30a)])&&(questionStates[currentQuestionIndex][_0x610954(0x226)]=_0x3c8b29['qUvlt'],stats[_0x610954(0x235)]++,stats['notAttempted']--),_0x3c8b29[_0x610954(0x178)](updateQuestionNav);_0x3c8b29[_0x610954(0x209)](saveProgress);}function processAnswer(){const _0x3ab524=_0x3e8868,_0x1f6efa={'uuWfw':function(_0x13283d,_0x47b825){return _0x13283d===_0x47b825;},'KEoii':function(_0x519564,_0x1e8633){return _0x519564===_0x1e8633;},'BpLjU':_0x3ab524(0x1bc),'DZZRh':function(_0x2e8f79){return _0x2e8f79();}},_0x1f6879=questionsData[currentQuestionIndex],_0x2ef501=_0x1f6879['correct_choice_id'];if(selectedOption===null)return;const _0x5452e5=_0x1f6879[_0x3ab524(0x1d2)][selectedOption],_0x2e2a81=_0x1f6efa[_0x3ab524(0x262)](_0x5452e5['id'],_0x2ef501);if(_0x1f6efa[_0x3ab524(0x2d8)](questionStates[currentQuestionIndex]['status'],_0x1f6efa[_0x3ab524(0x2a5)])){stats[_0x3ab524(0x235)]++,stats['notAttempted']--;if(_0x2e2a81)stats[_0x3ab524(0x233)]++;else stats[_0x3ab524(0x337)]++;}questionStates[currentQuestionIndex][_0x3ab524(0x226)]=_0x2e2a81?_0x3ab524(0x190):_0x3ab524(0x2d3),_0x1f6efa[_0x3ab524(0x1ea)](updateStats),showInlineFeedback(_0x2e2a81),updateQuestionNav();}function showInlineFeedback(_0x3ae17a){const _0x14dc56=_0x3e8868,_0x40525a={'WPWoK':_0x14dc56(0x1ae),'KLSwd':function(_0x292d2b,_0x772b4f){return _0x292d2b!==_0x772b4f;},'vPkOV':_0x14dc56(0x371),'MLruP':_0x14dc56(0x2d0),'wWNue':function(_0x35c556,_0xa639ea){return _0x35c556===_0xa639ea;},'DWXCx':_0x14dc56(0x190),'bBXPY':_0x14dc56(0x2d3),'PuFXK':function(_0x5f5bce,_0x2be265){return _0x5f5bce!==_0x2be265;},'kmyKI':_0x14dc56(0x1b2),'GZTPm':'optionsContainer','ACiie':'answered','kVECn':function(_0x3f8570){return _0x3f8570();}};if(currentMode!==_0x14dc56(0x352)&&_0x40525a[_0x14dc56(0x1ce)](currentMode,_0x40525a[_0x14dc56(0x256)]))return;const _0x442c47=document[_0x14dc56(0x2d4)](_0x40525a[_0x14dc56(0x172)]),_0x5aabe9=_0x442c47[_0x14dc56(0x1e2)](_0x14dc56(0x21b)),_0x4b6d80=questionsData[currentQuestionIndex],_0x5edcc7=_0x4b6d80[_0x14dc56(0x25c)];let _0x1f3926=_0x4b6d80['choices'][_0x14dc56(0x192)](_0x414b60=>_0x414b60['id']===_0x5edcc7);_0x442c47[_0x14dc56(0x2dc)][_0x14dc56(0xe9)](_0x40525a[_0x14dc56(0x240)]),_0x5aabe9[_0x14dc56(0x32d)]((_0x1fa216,_0x1e6437)=>{const _0x544e41=_0x14dc56,_0x510110={'zNSzK':_0x40525a[_0x544e41(0x2be)]};if(_0x40525a[_0x544e41(0x293)](_0x40525a[_0x544e41(0x2c4)],_0x40525a[_0x544e41(0x2c4)]))_0x529c54[_0x544e41(0x2dc)][_0x544e41(0xe9)](_0x510110['zNSzK']);else{_0x1fa216[_0x544e41(0x2dc)][_0x544e41(0x1a7)](_0x40525a['MLruP']);if(_0x40525a['wWNue'](_0x1e6437,_0x1f3926))_0x1fa216[_0x544e41(0x2dc)]['add'](_0x40525a[_0x544e41(0x2b0)]);else{if(_0x40525a[_0x544e41(0x1a6)](_0x1e6437,selectedOption)&&!_0x3ae17a)_0x1fa216[_0x544e41(0x2dc)]['add'](_0x40525a[_0x544e41(0x154)]);}}}),_0x40525a[_0x14dc56(0x34f)](showSolution);}function showSolution(){const _0x1c4e99=_0x3e8868,_0x37ee7={'PADlF':function(_0xbb3431,_0x18588f){return _0xbb3431>_0x18588f;},'HkMUQ':function(_0x5a499b,_0x20c8b2){return _0x5a499b-_0x20c8b2;},'TIJCt':function(_0x10a46b){return _0x10a46b();},'TixDB':function(_0x2cdd53){return _0x2cdd53();},'TWeSr':function(_0x4bd555,_0x62de94){return _0x4bd555===_0x62de94;},'Auprc':_0x1c4e99(0x2ae),'WHhJa':_0x1c4e99(0x266),'qbSUB':function(_0xaff820,_0x5e3361){return _0xaff820!==_0x5e3361;},'ZNUgv':_0x1c4e99(0x1b2),'AoELF':_0x1c4e99(0x2e0),'zmPqh':'solutionVideo','oghbY':_0x1c4e99(0x1ae),'LfBqu':_0x1c4e99(0x2d7),'AyTSz':function(_0x44eaa2,_0x39148e,_0x63fafe){return _0x44eaa2(_0x39148e,_0x63fafe);},'UBctU':_0x1c4e99(0x296)};if(currentMode!==_0x1c4e99(0x352)&&_0x37ee7[_0x1c4e99(0xe7)](currentMode,_0x37ee7['ZNUgv']))return;const _0x50c462=questionsData[currentQuestionIndex];document[_0x1c4e99(0x2d4)](_0x37ee7['AoELF'])['innerHTML']=_0x50c462[_0x1c4e99(0x123)]||_0x1c4e99(0x12b);const _0x5c41f4=document[_0x1c4e99(0x2d4)](_0x37ee7[_0x1c4e99(0x1f2)]),_0xe26944=document[_0x1c4e99(0x2d4)](_0x1c4e99(0x1db)),_0x3a81ff=_0x50c462[_0x1c4e99(0x21a)];if(_0x3a81ff){_0x5c41f4[_0x1c4e99(0x2dc)][_0x1c4e99(0x1a7)](_0x37ee7[_0x1c4e99(0x1d6)]);if(_0x3a81ff['includes'](_0x37ee7[_0x1c4e99(0x15a)]))_0x37ee7[_0x1c4e99(0x196)](setupVideo,_0xe26944,_0x3a81ff);else _0xe26944[_0x1c4e99(0x12c)]=_0x3a81ff;}else _0x5c41f4[_0x1c4e99(0x2dc)][_0x1c4e99(0xe9)](_0x37ee7[_0x1c4e99(0x1d6)]);const _0x2c8be0=document[_0x1c4e99(0x2d4)](_0x1c4e99(0x155));_0x2c8be0[_0x1c4e99(0x2a7)]='';_0x50c462['explanation_audio_eng']&&(_0x2c8be0[_0x1c4e99(0x2a7)]+=_0x1c4e99(0x290)+_0x50c462[_0x1c4e99(0x1d8)]+'\x22\x20controls\x20class=\x22w-full\x22></audio></div>');_0x50c462[_0x1c4e99(0x339)]&&(_0x2c8be0[_0x1c4e99(0x2a7)]+='<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish\x20Explanation:</p><audio\x20src=\x22'+_0x50c462['explanation_audio_hin']+'\x22\x20controls\x20class=\x22w-full\x22></audio></div>');const _0x22a0eb=document[_0x1c4e99(0x2d4)](_0x37ee7['UBctU']);_0x22a0eb['innerHTML']='',_0x50c462[_0x1c4e99(0x171)]&&_0x50c462[_0x1c4e99(0x171)][_0x1c4e99(0x32d)](_0x123e3f=>{const _0x4c1181=_0x1c4e99,_0x55659b={'iaVPG':function(_0x596d1a,_0x526769){const _0x265874=_0x2020;return _0x37ee7[_0x265874(0x2f9)](_0x596d1a,_0x526769);},'NdRNL':function(_0x4b06f9,_0xf59aca){const _0x160c89=_0x2020;return _0x37ee7[_0x160c89(0x242)](_0x4b06f9,_0xf59aca);},'xEXwa':function(_0x63dc47){return _0x37ee7['TIJCt'](_0x63dc47);},'dfgkZ':function(_0x21e71e){const _0x2c3de4=_0x2020;return _0x37ee7[_0x2c3de4(0x268)](_0x21e71e);}};if(_0x37ee7['TWeSr'](_0x37ee7[_0x4c1181(0x13a)],_0x37ee7[_0x4c1181(0x1a3)]))_0x55659b['iaVPG'](_0x3cf51e,0x0)&&(_0x2a0590&&(_0x53123a[_0x4dde1f][_0x4c1181(0x15f)]+=_0x55659b[_0x4c1181(0xd0)](_0x52076d['now'](),_0xf36463)),_0xef7c46--,_0x55659b[_0x4c1181(0xf2)](_0x339dee),_0x55659b['dfgkZ'](_0x212627));else{if(_0x123e3f)_0x22a0eb['innerHTML']+=_0x4c1181(0x18a)+_0x123e3f+_0x4c1181(0x29f);}}),document[_0x1c4e99(0x2d4)](_0x1c4e99(0x2ad))[_0x1c4e99(0x2dc)]['remove'](_0x37ee7[_0x1c4e99(0x1d6)]);}function submitQuiz(){const _0x523a65=_0x3e8868,_0x5d67f6={'LaUiH':'correct','RbThb':function(_0x1f256b,_0xcb0e31){return _0x1f256b===_0xcb0e31;},'gosiM':_0x523a65(0x163),'ahKXj':function(_0x519b6f,_0x1bce29){return _0x519b6f!==_0x1bce29;},'FZllK':function(_0x5d1ad1,_0x4f432b){return _0x5d1ad1===_0x4f432b;},'FlGsf':function(_0x2e01c7,_0x14aac6){return _0x2e01c7(_0x14aac6);},'wAbNs':function(_0x299eed,_0xbebc3b){return _0x299eed-_0xbebc3b;},'BLAbi':_0x523a65(0xdc),'jjKsY':function(_0x184ab3,_0xf78167){return _0x184ab3+_0xf78167;},'BiGHs':function(_0x3e8203){return _0x3e8203();},'WELeq':function(_0x5ce585,_0x3d96fd,_0x10986f,_0x1de500,_0x17fd13){return _0x5ce585(_0x3d96fd,_0x10986f,_0x1de500,_0x17fd13);},'fLPsL':function(_0x452952,_0x160041){return _0x452952-_0x160041;}};if(timer)_0x5d67f6['FlGsf'](clearInterval,timer);if(!_0x5d67f6[_0x523a65(0x217)](confirm,'Are\x20you\x20sure\x20you\x20want\x20to\x20submit\x20the\x20quiz?'))return;isQuizCompleted=!![];let _0x2d7367=0x0,_0x5cb090=0x0;const _0x533ac0=_0x5d67f6[_0x523a65(0x12e)](Date[_0x523a65(0xf7)](),quizStartTime);questionsData[_0x523a65(0x32d)]((_0x5e57b3,_0x3ffe89)=>{const _0x4afc3b=_0x523a65,_0x24f199={'lERCN':_0x5d67f6[_0x4afc3b(0x186)],'gEzUg':function(_0x38e8cc,_0x4ae3be){const _0x1b1313=_0x4afc3b;return _0x5d67f6[_0x1b1313(0x33e)](_0x38e8cc,_0x4ae3be);},'XLOHR':_0x4afc3b(0x2d3)};if(_0x5d67f6[_0x4afc3b(0x21f)]!==_0x4afc3b(0x341)){const _0x44222a=questionStates[_0x3ffe89];_0x5d67f6[_0x4afc3b(0x329)](_0x44222a[_0x4afc3b(0x285)],null)&&(_0x5d67f6[_0x4afc3b(0x344)](_0x5e57b3[_0x4afc3b(0x1d2)][_0x44222a['selectedAnswer']]['id'],_0x5e57b3[_0x4afc3b(0x25c)])?(_0x2d7367++,_0x44222a[_0x4afc3b(0x226)]=_0x4afc3b(0x190)):(_0x5cb090++,_0x44222a['status']=_0x4afc3b(0x2d3)));}else{_0x3d04ca[_0x4afc3b(0x2dc)][_0x4afc3b(0x1a7)](_0x4afc3b(0x2d0));if(_0x36b689===_0x43cd70)_0x5077d8[_0x4afc3b(0x2dc)][_0x4afc3b(0xe9)](_0x24f199[_0x4afc3b(0x28e)]);else{if(_0x24f199[_0x4afc3b(0x124)](_0xc31763,_0x30e284)&&!_0xc5c89f)_0x1ce30a[_0x4afc3b(0x2dc)][_0x4afc3b(0xe9)](_0x24f199['XLOHR']);}}});const _0x206a0d=JSON['parse'](localStorage[_0x523a65(0x31c)](_0x5d67f6['BLAbi']))||[];_0x206a0d['push']({'quizName':quizName,'hierarchy':hierarchy,'timestamp':Date[_0x523a65(0xf7)](),'totalTime':_0x533ac0,'stats':{'correct':_0x2d7367,'incorrect':_0x5cb090,'notAttempted':questionsData[_0x523a65(0x303)]-_0x5d67f6['jjKsY'](_0x2d7367,_0x5cb090)}}),localStorage[_0x523a65(0xfc)](_0x5d67f6[_0x523a65(0x2bd)],JSON[_0x523a65(0x328)](_0x206a0d)),stats[_0x523a65(0x233)]=_0x2d7367,stats[_0x523a65(0x337)]=_0x5cb090,_0x5d67f6[_0x523a65(0x30c)](markQuizAsCompleted),_0x5d67f6['WELeq'](showPerformanceAnalysis,_0x2d7367,_0x5cb090,_0x5d67f6['fLPsL'](questionsData[_0x523a65(0x303)],_0x5d67f6[_0x523a65(0x143)](_0x2d7367,_0x5cb090)),_0x533ac0);}function showPerformanceAnalysis(_0x1ca6b6,_0x7ed28f,_0x15b097,_0x48a3cd){const _0x2aff06=_0x3e8868,_0x2160cb={'IQfXi':'performanceModal','MMsIC':function(_0x31303b,_0x41054f){return _0x31303b>_0x41054f;},'fhyMQ':function(_0xb6bfd8,_0x1f8b96){return _0xb6bfd8*_0x1f8b96;},'CBgwH':function(_0x5ab6a8,_0x2d1c75){return _0x5ab6a8+_0x2d1c75;},'rVoCI':function(_0x509672,_0x2904f4){return _0x509672*_0x2904f4;},'wqRPy':_0x2aff06(0x359),'rdLkX':function(_0x29f3db,_0x5e5f6b){return _0x29f3db-_0x5e5f6b;},'uRXbl':function(_0x38d3ed,_0x54ec27){return _0x38d3ed*_0x54ec27;},'iyHWH':function(_0x2aab0e,_0x223246){return _0x2aab0e/_0x223246;},'Cdlyw':'accuracyScore','ZkaYW':_0x2aff06(0x160),'rWPcV':'correctResult','zmHWG':_0x2aff06(0x2b7),'fBJLI':_0x2aff06(0x376),'rTFIP':function(_0x3bccbf,_0x30f2de){return _0x3bccbf/_0x30f2de;},'csdZU':function(_0x2ab86f,_0x2b0e7d){return _0x2ab86f/_0x2b0e7d;},'wFDiS':'totalTimeResult','XwECG':function(_0x51ae17,_0x1a27fb){return _0x51ae17/_0x1a27fb;},'jgWNl':function(_0x5daaac,_0x4bb64a){return _0x5daaac/_0x4bb64a;},'zppMb':function(_0x472421,_0x14f8b8){return _0x472421%_0x14f8b8;},'NaMXL':'avgTimeResult'},_0x241d7e=document[_0x2aff06(0x2d4)](_0x2160cb['IQfXi']),_0xfe776=_0x2160cb[_0x2aff06(0x202)](_0x1ca6b6+_0x7ed28f,0x0)?Math['round'](_0x2160cb['fhyMQ'](_0x1ca6b6/_0x2160cb['CBgwH'](_0x1ca6b6,_0x7ed28f),0x64)):0x0,_0x3b7778=_0x2160cb[_0x2aff06(0x1f4)](_0x2160cb['rVoCI'](0x2,Math['PI']),0x41),_0x38307c=document[_0x2aff06(0x2d4)](_0x2160cb['wqRPy']);_0x38307c[_0x2aff06(0x1b1)][_0x2aff06(0x14a)]=_0x3b7778+'\x20'+_0x3b7778,_0x38307c['style'][_0x2aff06(0x2ce)]=_0x2160cb[_0x2aff06(0x2f4)](_0x3b7778,_0x2160cb[_0x2aff06(0x2ee)](_0x2160cb['iyHWH'](_0xfe776,0x64),_0x3b7778)),document['getElementById'](_0x2160cb['Cdlyw'])[_0x2aff06(0x322)]=_0xfe776+'%',document[_0x2aff06(0x2d4)](_0x2160cb[_0x2aff06(0x2da)])[_0x2aff06(0x322)]=questionsData[_0x2aff06(0x303)],document[_0x2aff06(0x2d4)](_0x2160cb['rWPcV'])[_0x2aff06(0x322)]=_0x1ca6b6,document['getElementById'](_0x2160cb[_0x2aff06(0x1c5)])['textContent']=_0x7ed28f,document[_0x2aff06(0x2d4)](_0x2160cb['fBJLI'])[_0x2aff06(0x322)]=_0x15b097;const _0x24f94d=Math[_0x2aff06(0x335)](_0x2160cb[_0x2aff06(0x2ba)](_0x48a3cd,0xea60)),_0x32869b=Math[_0x2aff06(0x335)](_0x2160cb[_0x2aff06(0x239)](_0x48a3cd%0xea60,0x3e8));document['getElementById'](_0x2160cb[_0x2aff06(0x365)])[_0x2aff06(0x322)]=_0x24f94d+':'+_0x32869b['toString']()['padStart'](0x2,'0');const _0x3363e8=_0x48a3cd/questionsData['length'],_0x23ad37=Math['floor'](_0x2160cb[_0x2aff06(0xdd)](_0x3363e8,0xea60)),_0x508796=Math[_0x2aff06(0x335)](_0x2160cb[_0x2aff06(0x2d5)](_0x2160cb[_0x2aff06(0x207)](_0x3363e8,0xea60),0x3e8));document[_0x2aff06(0x2d4)](_0x2160cb[_0x2aff06(0x1f6)])[_0x2aff06(0x322)]=_0x23ad37+':'+_0x508796[_0x2aff06(0x132)]()[_0x2aff06(0x215)](0x2,'0'),_0x241d7e[_0x2aff06(0x2dc)][_0x2aff06(0x1a7)](_0x2aff06(0x1ae));}function closePerformanceModal(){const _0x2130a4=_0x3e8868,_0x5acf66={'XfwTT':_0x2130a4(0x151),'BRSDc':_0x2130a4(0x1ae)};document[_0x2130a4(0x2d4)](_0x5acf66[_0x2130a4(0x139)])['classList'][_0x2130a4(0xe9)](_0x5acf66[_0x2130a4(0x137)]);}function reviewQuestions(){const _0x1149c2=_0x3e8868,_0x21cecd={'mDYzH':'modeModal','UJMae':'flex','glgXI':function(_0x54e992,_0x2d8e6f){return _0x54e992===_0x2d8e6f;},'TuYbe':_0x1149c2(0x199),'nEIiE':function(_0x5b2e91,_0x5b5c83){return _0x5b2e91===_0x5b5c83;},'KJmBA':function(_0xf32a9a,_0x47dbb2){return _0xf32a9a===_0x47dbb2;},'pmpYR':_0x1149c2(0x174),'knLWH':_0x1149c2(0x35d),'leWBO':function(_0x386c1a,_0x2e132e){return _0x386c1a+_0x2e132e;},'clFzU':function(_0x2ae056,_0x4c4f6d){return _0x2ae056===_0x4c4f6d;},'iAjVX':_0x1149c2(0x2e9),'lerjm':_0x1149c2(0x254),'Njskh':_0x1149c2(0x1dc),'ViHqs':'block','vBVCL':_0x1149c2(0x2cf),'fcnUj':'testModeLegend','hsDVk':'timed_study','eaWBK':'hidden','kzUsM':function(_0xb2c8df,_0x34582a){return _0xb2c8df>=_0x34582a;},'TYyCq':function(_0x5bff3d,_0x496387){return _0x5bff3d<_0x496387;},'okUIC':_0x1149c2(0x27f),'gILpA':_0x1149c2(0x2f7),'nLmXD':'GIfml','TeZZp':_0x1149c2(0xd2),'liWKx':_0x1149c2(0xff),'epGXy':_0x1149c2(0x2d3),'GnIBg':_0x1149c2(0x198),'OUNCJ':function(_0x3b9e8c,_0x305866){return _0x3b9e8c+_0x305866;},'eSLxw':function(_0x315278,_0x4be43a){return _0x315278===_0x4be43a;},'keZii':'green','fkhaq':_0x1149c2(0x2c2),'tytBa':_0x1149c2(0x1a4),'mZVbY':_0x1149c2(0x30e),'LCtZD':_0x1149c2(0x18c),'dOECc':function(_0x583811){return _0x583811();}};document['getElementById'](_0x21cecd[_0x1149c2(0x2e3)])['classList']['remove']('hidden');const _0x1978cc=document[_0x1149c2(0x2d4)](_0x21cecd[_0x1149c2(0x2b3)]);_0x1978cc['innerHTML']='',questionsData['forEach']((_0x37d476,_0x3985df)=>{const _0x22dbe7=_0x1149c2,_0x16dc8={'oUeUL':_0x22dbe7(0x2d0),'OdTog':function(_0x27ac02,_0x30f2db){const _0x57c0a7=_0x22dbe7;return _0x21cecd[_0x57c0a7(0x283)](_0x27ac02,_0x30f2db);},'sCDzA':_0x21cecd[_0x22dbe7(0x318)],'TCasZ':_0x22dbe7(0x1d3),'LKvcm':_0x21cecd[_0x22dbe7(0x1e9)],'pWGrI':_0x22dbe7(0x36e),'HUzlA':function(_0xe71d6d,_0x41ef88){return _0x21cecd['clFzU'](_0xe71d6d,_0x41ef88);},'yaiGm':'timed_exam','bWdLC':_0x21cecd[_0x22dbe7(0x142)],'uobOu':_0x21cecd['ViHqs'],'PVRxT':_0x21cecd['vBVCL'],'HNPor':_0x22dbe7(0x301),'benOy':_0x21cecd['fcnUj'],'HHtbE':_0x22dbe7(0x294),'KnuqW':_0x21cecd[_0x22dbe7(0x17d)],'INWGF':_0x21cecd[_0x22dbe7(0x1f5)],'ntbvZ':function(_0x31c99f,_0x2af6a4){const _0x5954be=_0x22dbe7;return _0x21cecd[_0x5954be(0x35c)](_0x31c99f,_0x2af6a4);},'YMEMf':function(_0x2e6eb4,_0x546ab8){const _0x2fac4b=_0x22dbe7;return _0x21cecd[_0x2fac4b(0x141)](_0x2e6eb4,_0x546ab8);},'lSXwC':function(_0x44e7e0){return _0x44e7e0();}},_0x2fdbc8=questionStates[_0x3985df],_0x3ccb4f=_0x37d476[_0x22dbe7(0x25c)];let _0x3bb13f=_0x21cecd['okUIC'],_0x2c80de=_0x22dbe7(0x15e);if(_0x2fdbc8[_0x22dbe7(0x285)]!==null){if(_0x21cecd[_0x22dbe7(0x11d)](_0x22dbe7(0x2f7),_0x21cecd[_0x22dbe7(0x25a)])){const _0x1682d5=_0x37d476[_0x22dbe7(0x1d2)][_0x2fdbc8[_0x22dbe7(0x285)]];_0x21cecd[_0x22dbe7(0x11d)](_0x1682d5['id'],_0x3ccb4f)?_0x21cecd[_0x22dbe7(0x325)]!==_0x21cecd[_0x22dbe7(0x206)]?(_0x3bb13f=_0x22dbe7(0x190),_0x2c80de=_0x21cecd[_0x22dbe7(0x1d5)]):_0x3a75fa[_0x22dbe7(0x2dc)][_0x22dbe7(0x15d)](_0x16dc8[_0x22dbe7(0x128)],_0x16dc8['OdTog'](_0x2b17e3,_0x1278e5)):(_0x3bb13f=_0x21cecd[_0x22dbe7(0x200)],_0x2c80de=_0x22dbe7(0x28f));}else _0x41509c(),_0x27eb13['getElementById'](_0x21cecd['mDYzH'])[_0x22dbe7(0x1b1)]['display']=_0x21cecd[_0x22dbe7(0x214)];}const _0x416098=document[_0x22dbe7(0x1c7)](_0x21cecd[_0x22dbe7(0x1f7)]);_0x416098['className']='review-question\x20'+_0x3bb13f;let _0x598fd1=(_0x37d476['choices']||[])[_0x22dbe7(0x197)]((_0x324002,_0x2fa91c)=>{const _0x36f611=_0x22dbe7;if(_0x21cecd[_0x36f611(0x350)](_0x36f611(0x25f),_0x21cecd['TuYbe'])){_0x7e133e=_0x8f41d7[_0x36f611(0xf7)]();const _0x3221d6=_0x4f1c48[_0x36f611(0x2d4)](_0x16dc8['sCDzA']),_0x56259e=_0x5c50e1[_0x36f611(0x2d4)](_0x16dc8['TCasZ']),_0x16b29b=_0x24e4ad[_0x36f611(0x2d4)](_0x16dc8[_0x36f611(0x126)]),_0x197beb=_0x16dc8[_0x36f611(0x1de)](_0x320a48,_0x16dc8[_0x36f611(0x1c4)])||_0x16dc8[_0x36f611(0x273)](_0x37b114,_0x16dc8[_0x36f611(0xf1)]);_0x56eb26[_0x36f611(0x2d4)](_0x16dc8[_0x36f611(0x2ea)])[_0x36f611(0x1b1)]['display']=_0x197beb?_0x36f611(0x301):_0x16dc8[_0x36f611(0x1df)],_0x4ecc3f['getElementById'](_0x16dc8[_0x36f611(0xde)])[_0x36f611(0x1b1)][_0x36f611(0x302)]=_0x197beb?_0x16dc8[_0x36f611(0x224)]:_0x36f611(0xe5),_0x6eacd0[_0x36f611(0x2d4)](_0x16dc8[_0x36f611(0x2c6)])['style'][_0x36f611(0x302)]=_0x197beb?_0x16dc8[_0x36f611(0x1df)]:_0x16dc8[_0x36f611(0x224)],_0x2d73cf['getElementById']('submitSection')['style']['display']=_0x197beb?_0x16dc8['uobOu']:_0x16dc8[_0x36f611(0x224)],_0x3221d6[_0x36f611(0x1b1)][_0x36f611(0x302)]=_0x197beb?_0x36f611(0x301):_0x36f611(0x294),_0x56259e[_0x36f611(0x1b1)][_0x36f611(0x302)]=_0x197beb?_0x16dc8[_0x36f611(0x300)]:_0x16dc8[_0x36f611(0x224)],_0x16b29b[_0x36f611(0x1b1)][_0x36f611(0x302)]=_0x197beb?_0x16dc8[_0x36f611(0x300)]:_0x16dc8[_0x36f611(0x224)],(_0x45aab2===_0x16dc8[_0x36f611(0x216)]||_0x16dc8['HUzlA'](_0x354d0f,_0x16dc8[_0x36f611(0xf1)]))&&_0x2c6fc3[_0x36f611(0x2d4)](_0x36f611(0x2bf))[_0x36f611(0x2dc)][_0x36f611(0x1a7)](_0x16dc8[_0x36f611(0x278)]),!_0x455e65(_0x4b518c)&&_0x16dc8[_0x36f611(0x36f)](_0x5b24ea,0x0)&&_0x16dc8[_0x36f611(0x31e)](_0x443924,_0x22beff['length'])&&(_0x175055=_0x48afd4),_0x10470d(),_0x16dc8[_0x36f611(0x23e)](_0x3ad082),_0x16dc8['lSXwC'](_0xce7783),_0x16dc8[_0x36f611(0x23e)](_0x1e989a);}else{const _0x3179aa=_0x21cecd[_0x36f611(0x165)](_0x2fdbc8[_0x36f611(0x285)],_0x2fa91c),_0x4cb9e0=_0x21cecd[_0x36f611(0x11d)](_0x324002['id'],_0x3ccb4f);let _0x52519a=_0x36f611(0xee);if(_0x4cb9e0)_0x52519a=_0x21cecd[_0x36f611(0x35b)];else{if(_0x3179aa)_0x52519a=_0x21cecd[_0x36f611(0x148)];}return _0x36f611(0x26c)+_0x52519a+_0x36f611(0x131)+String[_0x36f611(0x373)](_0x21cecd[_0x36f611(0x2e1)](0x41,_0x2fa91c))+_0x36f611(0x27d)+_0x324002['text']+_0x36f611(0x36d);}})[_0x22dbe7(0x369)]('');const _0x231cc7=_0x37d476[_0x22dbe7(0x21a)]?_0x22dbe7(0x1e3)+_0x3985df+_0x22dbe7(0x20f)+_0x37d476[_0x22dbe7(0x21a)]+_0x22dbe7(0x37c):'';let _0xa11404='';if(_0x37d476['explanation_audio_eng'])_0xa11404+=_0x22dbe7(0x237)+_0x37d476[_0x22dbe7(0x1d8)]+'\x22\x20controls\x20class=\x22w-full\x22></audio></div>';if(_0x37d476[_0x22dbe7(0x339)])_0xa11404+=_0x22dbe7(0x203)+_0x37d476['explanation_audio_hin']+_0x22dbe7(0x36a);let _0x5163fb=(_0x37d476['explanation_images']||[])[_0x22dbe7(0x197)](_0x4578c1=>_0x4578c1?'<div\x20class=\x22mt-4\x22><img\x20src=\x22'+_0x4578c1+_0x22dbe7(0x29f):'')[_0x22dbe7(0x369)]('');_0x416098[_0x22dbe7(0x2a7)]=_0x22dbe7(0xf0)+_0x21cecd[_0x22dbe7(0x181)](_0x3985df,0x1)+'</h4>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<span\x20class=\x22text-sm\x20px-3\x20py-1\x20rounded-full\x20bg-'+(_0x21cecd[_0x22dbe7(0x2a4)](_0x3bb13f,_0x22dbe7(0x190))?_0x21cecd[_0x22dbe7(0x327)]:_0x3bb13f===_0x21cecd[_0x22dbe7(0x200)]?_0x21cecd[_0x22dbe7(0x145)]:_0x22dbe7(0xe4))+_0x22dbe7(0x204)+_0x2c80de+_0x22dbe7(0x2e7)+_0x37d476[_0x22dbe7(0x1a2)]+_0x22dbe7(0x358)+_0x598fd1+_0x22dbe7(0x35a)+(_0x37d476[_0x22dbe7(0x123)]||_0x21cecd['tytBa'])+_0x22dbe7(0x15c)+_0x231cc7+_0x22dbe7(0x23c)+_0xa11404+_0x22dbe7(0x23c)+_0x5163fb+_0x22dbe7(0x299),_0x1978cc[_0x22dbe7(0x277)](_0x416098);}),_0x21cecd[_0x1149c2(0x32c)](initializeReviewVideos);}function initializeReviewVideos(){const _0x86fcda=_0x3e8868,_0x3709c4={'inpPk':function(_0x5a0e92){return _0x5a0e92();},'nBzqh':function(_0x4b6dd3,_0x2f6b9f){return _0x4b6dd3!==_0x2f6b9f;},'gtwAQ':_0x86fcda(0x2e2),'paKxs':_0x86fcda(0x221),'klvRx':function(_0x4dceb9,_0x57944a,_0x4591b7){return _0x4dceb9(_0x57944a,_0x4591b7);},'yEfRh':function(_0x4a9363,_0xed03da){return _0x4a9363===_0xed03da;},'enPEY':_0x86fcda(0x1c0),'SypKQ':_0x86fcda(0x245),'mztoT':'video[data-src]'};document[_0x86fcda(0x1e2)](_0x3709c4[_0x86fcda(0x227)])[_0x86fcda(0x32d)](_0x3a473d=>{const _0x2b38e7=_0x86fcda;if(_0x3709c4[_0x2b38e7(0x32e)](_0x3709c4[_0x2b38e7(0x12f)],_0x3709c4['paKxs'])){const _0x3b1694=_0x3a473d[_0x2b38e7(0x238)][_0x2b38e7(0x12c)];if(_0x3b1694&&_0x3b1694[_0x2b38e7(0x374)]('.m3u8'))_0x3709c4[_0x2b38e7(0x183)](setupVideo,_0x3a473d,_0x3b1694);else _0x3b1694&&(_0x3709c4[_0x2b38e7(0x159)](_0x3709c4[_0x2b38e7(0x29a)],_0x3709c4['SypKQ'])?(_0x38bfd7&&(_0x54d08a[_0x2c1c11][_0x2b38e7(0x15f)]+=_0x2bdc8d[_0x2b38e7(0xf7)]()-_0x1bd0c9),_0x1cf44d--,_0x323b13(),_0x3709c4[_0x2b38e7(0x162)](_0x5e9984)):_0x3a473d[_0x2b38e7(0x12c)]=_0x3b1694);}else{const _0x57da61=_0x429151?function(){const _0x249520=_0x2b38e7;if(_0x1e970d){const _0x4c70d1=_0x54689f[_0x249520(0xd7)](_0x3628a0,arguments);return _0x4b24e6=null,_0x4c70d1;}}:function(){};return _0x27d793=![],_0x57da61;}});}function retakeQuiz(){const _0x4fa7f3=_0x3e8868,_0x1f734e={'DWQZS':'userHistory','BsvYX':_0x4fa7f3(0x17c),'bplqI':function(_0x213df5,_0x5295a2){return _0x213df5(_0x5295a2);},'MvIBx':_0x4fa7f3(0x261),'kLiHz':function(_0x735ce2,_0x2fd61a){return _0x735ce2!==_0x2fd61a;},'GDgHQ':'WgGJc','gFnbR':_0x4fa7f3(0x336),'xDmGy':function(_0x2034f0){return _0x2034f0();}};if(_0x1f734e[_0x4fa7f3(0xcc)](confirm,_0x1f734e[_0x4fa7f3(0xcf)])){if(window[_0x4fa7f3(0x194)]['pathname']['endsWith']('custom_quiz.html')){if(_0x1f734e[_0x4fa7f3(0x21e)](_0x1f734e['GDgHQ'],_0x1f734e[_0x4fa7f3(0x10f)])){const _0x2effe1=_0x48d81e[_0x4fa7f3(0x307)](_0x5b6ee0['getItem'](_0x1f734e[_0x4fa7f3(0x304)]))||{},_0x18f376=_0x5331ab[_0x4fa7f3(0x303)],_0x4cec81=_0xaddd15['correctAnswers']||0x0;_0x2effe1[_0x411f26]={'score':_0x4cec81,'total':_0x18f376,'status':_0x1f734e[_0x4fa7f3(0x188)],'completedOn':new _0x4ed50d()[_0x4fa7f3(0x1f0)]()},_0x5ebcab['setItem'](_0x1f734e[_0x4fa7f3(0x304)],_0x19bf6d[_0x4fa7f3(0x328)](_0x2effe1));}else localStorage['removeItem'](_0x1f734e[_0x4fa7f3(0x284)]);}_0x1f734e[_0x4fa7f3(0x32b)](clearProgress),location[_0x4fa7f3(0x117)]();}}function loadBookmarkedQuestions(){const _0x248b61=_0x3e8868,_0x552b4d={'mRYko':_0x248b61(0x336),'KpIhC':function(_0x1359a6,_0x12ade4){return _0x1359a6<_0x12ade4;},'TfExZ':function(_0x28f031,_0x319dae){return _0x28f031!==_0x319dae;},'sRmxn':_0x248b61(0x2d1),'IBhhT':_0x248b61(0x109)},_0x572ac6=JSON[_0x248b61(0x307)](localStorage[_0x248b61(0x31c)](_0x552b4d[_0x248b61(0x334)]))||[];_0x572ac6['forEach'](_0x35dcea=>{const _0x141b7d=_0x248b61,_0x5ac874={'HCEZG':_0x552b4d['mRYko']};_0x35dcea['quizFile'][_0x141b7d(0x374)](quizName['toLowerCase']()[_0x141b7d(0x1c2)](/ /g,'-'))&&(_0x552b4d[_0x141b7d(0x1cf)](_0x35dcea[_0x141b7d(0x1eb)],questionsData[_0x141b7d(0x303)])&&(_0x552b4d['TfExZ'](_0x141b7d(0x228),_0x552b4d['sRmxn'])?questionStates[_0x35dcea[_0x141b7d(0x1eb)]][_0x141b7d(0x225)]=!![]:_0x4737e2[_0x141b7d(0x1da)](_0x5ac874[_0x141b7d(0x14c)])));});}function toggleBookmark(){const _0x401ff3=_0x3e8868,_0x21b615={'OUPpu':_0x401ff3(0x109),'TAams':function(_0x16670f){return _0x16670f();}},_0x2a7490=!questionStates[currentQuestionIndex][_0x401ff3(0x225)];questionStates[currentQuestionIndex][_0x401ff3(0x225)]=_0x2a7490;let _0x2c5dcd=JSON[_0x401ff3(0x307)](localStorage[_0x401ff3(0x31c)](_0x21b615['OUPpu']))||[];if(_0x2a7490){const _0x1e6615={'quizName':quizName,'quizFile':window[_0x401ff3(0x194)][_0x401ff3(0x2fc)][_0x401ff3(0x1b4)]('/')[_0x401ff3(0x2a2)](),'questionIndex':currentQuestionIndex,'question':questionsData[currentQuestionIndex],'hierarchy':hierarchy,'timestamp':Date[_0x401ff3(0xf7)]()};_0x2c5dcd[_0x401ff3(0x210)](_0x1e6615);}else _0x2c5dcd=_0x2c5dcd[_0x401ff3(0xd3)](_0x20e928=>!(_0x20e928[_0x401ff3(0x161)][_0x401ff3(0x374)](quizName[_0x401ff3(0x173)]()[_0x401ff3(0x1c2)](/ /g,'-'))&&_0x20e928[_0x401ff3(0x1eb)]===currentQuestionIndex));localStorage['setItem'](_0x21b615[_0x401ff3(0x1ab)],JSON[_0x401ff3(0x328)](_0x2c5dcd)),updateBookmarkButton(),_0x21b615[_0x401ff3(0x10a)](updateQuestionNav);}function updateBookmarkButton(){const _0x3bc776=_0x3e8868,_0x37a74c={'IFXtc':_0x3bc776(0x310),'hARxj':'glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-yellow-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','oatHb':_0x3bc776(0x28b),'cLxKW':_0x3bc776(0x19f)},_0x102605=document[_0x3bc776(0x2d4)](_0x3bc776(0x2e9)),_0x2fc2c6=document[_0x3bc776(0x2d4)](_0x3bc776(0x111)),_0x23dfe4=questionStates[currentQuestionIndex]['bookmarked'];_0x102605[_0x3bc776(0x272)]=_0x23dfe4?_0x37a74c['IFXtc']:_0x37a74c[_0x3bc776(0x281)],_0x2fc2c6[_0x3bc776(0x322)]=_0x23dfe4?_0x37a74c[_0x3bc776(0x2f8)]:_0x37a74c['cLxKW'];}function toggleMarkForReview(){const _0x3537a2=_0x3e8868,_0x2e9f07={'PYJgi':function(_0xc28368){return _0xc28368();},'eWIqo':function(_0x2d8010){return _0x2d8010();}};questionStates[currentQuestionIndex][_0x3537a2(0x116)]=!questionStates[currentQuestionIndex][_0x3537a2(0x116)],_0x2e9f07[_0x3537a2(0x2b6)](updateMarkReviewButton),_0x2e9f07['eWIqo'](updateQuestionNav);}function updateMarkReviewButton(){const _0x54a46b=_0x3e8868,_0x2cb83f={'gUIpZ':_0x54a46b(0x1d3),'IVgoz':_0x54a46b(0x320),'kfnrZ':_0x54a46b(0x170),'HYgaO':_0x54a46b(0x361)},_0xf7ba23=document['getElementById'](_0x2cb83f[_0x54a46b(0x193)]),_0x3bfcdd=document['getElementById'](_0x2cb83f[_0x54a46b(0x309)]),_0x559845=questionStates[currentQuestionIndex][_0x54a46b(0x116)];_0xf7ba23[_0x54a46b(0x272)]=_0x559845?_0x2cb83f[_0x54a46b(0x16f)]:_0x2cb83f[_0x54a46b(0x29d)],_0x3bfcdd[_0x54a46b(0x322)]=_0x559845?'Marked':_0x54a46b(0x134);}function previousQuestion(){const _0x391a02=_0x3e8868,_0x72bf24={'oQGDC':function(_0x400f53){return _0x400f53();},'CKNrQ':function(_0x1e04de,_0x372df0){return _0x1e04de>_0x372df0;},'qpNyB':function(_0x210d19,_0x2e778d){return _0x210d19!==_0x2e778d;},'kpFXf':_0x391a02(0x23b),'kbNwG':_0x391a02(0xef),'aPxZF':function(_0x5cc9c,_0x3aaf74){return _0x5cc9c-_0x3aaf74;}};_0x72bf24[_0x391a02(0x24d)](currentQuestionIndex,0x0)&&(_0x72bf24[_0x391a02(0x22d)](_0x72bf24[_0x391a02(0x229)],_0x72bf24[_0x391a02(0x14f)])?(questionStartTime&&(questionStates[currentQuestionIndex][_0x391a02(0x15f)]+=_0x72bf24[_0x391a02(0x34d)](Date['now'](),questionStartTime)),currentQuestionIndex--,_0x72bf24['oQGDC'](displayQuestion),saveProgress()):_0x72bf24[_0x391a02(0x1b8)](_0xbb967a));}function nextQuestion(){const _0xb7f96a=_0x3e8868,_0x2c21ca={'ONyuz':function(_0x349b15){return _0x349b15();},'EFdAo':function(_0x4737d2,_0x545c94){return _0x4737d2-_0x545c94;},'QhvVy':function(_0x32d84e,_0x52bffc){return _0x32d84e===_0x52bffc;},'RNgDF':_0xb7f96a(0x1aa),'WCsaj':'yrYKt','Nkhra':_0xb7f96a(0x36e),'kkKfT':function(_0x12f72d,_0x473303){return _0x12f72d(_0x473303);},'oSMKc':_0xb7f96a(0x195),'pSVvT':function(_0x1aa788){return _0x1aa788();},'XcwcR':function(_0x2ad1ce,_0x59558c){return _0x2ad1ce(_0x59558c);},'PGUau':_0xb7f96a(0x31d)};questionStartTime&&(questionStates[currentQuestionIndex][_0xb7f96a(0x15f)]+=_0x2c21ca['EFdAo'](Date[_0xb7f96a(0xf7)](),questionStartTime)),currentQuestionIndex<questionsData[_0xb7f96a(0x303)]-0x1?_0x2c21ca[_0xb7f96a(0x244)](_0x2c21ca[_0xb7f96a(0x333)],_0x2c21ca['WCsaj'])?_0x2c21ca['ONyuz'](_0x2a559a):(currentQuestionIndex++,_0x2c21ca['ONyuz'](displayQuestion),saveProgress()):currentMode===_0x2c21ca['Nkhra']||_0x2c21ca[_0xb7f96a(0x244)](currentMode,_0xb7f96a(0xda))?_0x2c21ca[_0xb7f96a(0x35f)](confirm,_0x2c21ca[_0xb7f96a(0x2c3)])&&_0x2c21ca[_0xb7f96a(0x129)](submitQuiz):_0x2c21ca[_0xb7f96a(0x16e)](confirm,_0x2c21ca[_0xb7f96a(0x24a)])&&(currentQuestionIndex=0x0,_0x2c21ca[_0xb7f96a(0x33c)](displayQuestion),saveProgress());}function startTimer(){const _0x143ed5=_0x3e8868,_0x2bb70c={'lWwcC':_0x143ed5(0x2d7),'NAfcK':function(_0x1d1b1c,_0x4f4d79,_0x357ed7){return _0x1d1b1c(_0x4f4d79,_0x357ed7);},'eiVAl':_0x143ed5(0x247),'wRORZ':function(_0x2f198e){return _0x2f198e();},'NwOfl':_0x143ed5(0xce),'gfaaJ':_0x143ed5(0x1bb),'wyhhP':function(_0x537376,_0x4fa648){return _0x537376<=_0x4fa648;},'PQiAr':function(_0x73f993,_0x524a98){return _0x73f993(_0x524a98);},'YtCAr':_0x143ed5(0xda),'eCqYO':function(_0x3ef099,_0x4f03a3){return _0x3ef099!==_0x4f03a3;},'kYrmq':'teQxj','eYWfL':'btDIf','dHSnr':'ImGkQ','sXCVR':_0x143ed5(0x30f)};if(timer)_0x2bb70c[_0x143ed5(0x28c)](clearInterval,timer);timeRemaining=0x78,_0x2bb70c[_0x143ed5(0x127)](updateTimerDisplay),timer=setInterval(()=>{const _0x59b55e=_0x143ed5,_0xf378c6={'SoPCC':function(_0x4d8811){const _0x506f6d=_0x2020;return _0x2bb70c[_0x506f6d(0x127)](_0x4d8811);}};if(_0x2bb70c[_0x59b55e(0x368)]===_0x2bb70c[_0x59b55e(0x1ef)]){const _0x1da7b6=_0xbe7209[_0x59b55e(0x238)][_0x59b55e(0x12c)];if(_0x1da7b6&&_0x1da7b6[_0x59b55e(0x374)](_0x2bb70c[_0x59b55e(0x27a)]))_0x2bb70c[_0x59b55e(0xf5)](_0x344f8f,_0x7ab28f,_0x1da7b6);else _0x1da7b6&&(_0x15e043[_0x59b55e(0x12c)]=_0x1da7b6);}else{timeRemaining--,_0x2bb70c[_0x59b55e(0x127)](updateTimerDisplay);if(_0x2bb70c[_0x59b55e(0x2c8)](timeRemaining,0x0)){_0x2bb70c[_0x59b55e(0x28c)](clearInterval,timer);if(currentMode===_0x2bb70c[_0x59b55e(0x351)]){if(_0x2bb70c['eCqYO'](_0x2bb70c['kYrmq'],_0x2bb70c['eYWfL']))submitQuiz();else return _0x264ccd[_0x59b55e(0x132)]()['search'](LplkYK['eiVAl'])['toString']()[_0x59b55e(0x101)](_0x43b26a)['search']('(((.+)+)+)+$');}else _0x2bb70c[_0x59b55e(0x220)](_0x2bb70c[_0x59b55e(0x13c)],_0x2bb70c[_0x59b55e(0x314)])?_0x2bb70c[_0x59b55e(0x127)](nextQuestion):(_0x5c9517[_0x9beb13][_0x59b55e(0x116)]=!_0x34529d[_0x1bdd19]['markedForReview'],_0xf378c6[_0x59b55e(0x105)](_0x4cb4fa),_0xf378c6[_0x59b55e(0x105)](_0x597155));}}},0x3e8);}function updateTimerDisplay(){const _0x1418f7=_0x3e8868,_0x3bbcf3={'tjoAy':function(_0x44a54f,_0x462f4d){return _0x44a54f%_0x462f4d;},'chHEi':function(_0xe09f40,_0x35b0ef){return _0xe09f40+_0x35b0ef;},'mimBg':function(_0x4d1acc,_0x3af70c){return _0x4d1acc+_0x3af70c;}},_0x5cb3e8=Math[_0x1418f7(0x335)](timeRemaining/0x3c),_0x5bedc4=_0x3bbcf3[_0x1418f7(0xed)](timeRemaining,0x3c);document[_0x1418f7(0x2d4)]('timeDisplay')[_0x1418f7(0x322)]=_0x3bbcf3['chHEi'](_0x3bbcf3[_0x1418f7(0x18b)](_0x5cb3e8,':'),_0x5bedc4['toString']()[_0x1418f7(0x215)](0x2,'0'));}function toggleSidebar(){const _0x36aa34=_0x3e8868,_0x297ee7={'sBQLu':_0x36aa34(0x24c),'yPLYD':_0x36aa34(0x1fe)};document['getElementById'](_0x297ee7[_0x36aa34(0xfd)])[_0x36aa34(0x2dc)][_0x36aa34(0x15d)](_0x297ee7[_0x36aa34(0x1f3)]);}document[_0x3e8868(0x33f)](_0x3e8868(0x144),()=>{const _0x41848e=_0x3e8868,_0x45da77={'MQwfE':function(_0x1c249d,_0xfe9a1c){return _0x1c249d===_0xfe9a1c;},'tYpYZ':'incorrect','FceLO':_0x41848e(0x122),'xhjdR':function(_0x15ce62){return _0x15ce62();},'bcxOv':_0x41848e(0x1e8),'FGWhj':_0x41848e(0x301),'HMsxC':_0x41848e(0x294),'UfUeU':'custom_quiz.html','jdCyD':function(_0x41b40c,_0x2686e3){return _0x41b40c!==_0x2686e3;},'KdSiP':_0x41848e(0xf8),'Xerjs':function(_0x2ee752){return _0x2ee752();},'pPJmA':function(_0x2520f2,_0x21122d){return _0x2520f2!==_0x21122d;},'UGcDB':_0x41848e(0x35e),'QvbBD':function(_0x4d52ac){return _0x4d52ac();}};if(resume)_0x45da77[_0x41848e(0x2b8)](loadProgress)?(document[_0x41848e(0x2d4)](_0x45da77[_0x41848e(0x2ff)])[_0x41848e(0x1b1)][_0x41848e(0x302)]=_0x45da77[_0x41848e(0x22b)],initializeQuiz()):(_0x45da77['xhjdR'](clearProgress),document[_0x41848e(0x2d4)](_0x45da77[_0x41848e(0x2ff)])[_0x41848e(0x1b1)][_0x41848e(0x302)]=_0x45da77['HMsxC']);else{if(!window['location'][_0x41848e(0x2fc)][_0x41848e(0x34e)](_0x45da77[_0x41848e(0x1a9)])){if(_0x45da77['jdCyD'](_0x45da77[_0x41848e(0x201)],_0x41848e(0x258)))_0x45da77[_0x41848e(0x107)](clearProgress),document[_0x41848e(0x2d4)](_0x41848e(0x1e8))[_0x41848e(0x1b1)][_0x41848e(0x302)]=_0x45da77[_0x41848e(0x2dd)];else{if(_0x45da77[_0x41848e(0x1f8)](_0x5f183f[_0x41848e(0x226)],_0x41848e(0x190)))_0x7c6386='nav-btn-correct';else{if(_0x45da77['MQwfE'](_0x3a2d41[_0x41848e(0x226)],_0x45da77[_0x41848e(0xe8)]))_0x43bf9e=_0x41848e(0x157);else _0x4a9dca=_0x45da77[_0x41848e(0x19c)];}}}else _0x45da77[_0x41848e(0x231)](_0x45da77['UGcDB'],_0x41848e(0x342))?_0x45da77[_0x41848e(0x1bd)](initializeQuiz):(_0xd8562=_0x45da77['tYpYZ'],_0x2a41e7=_0x41848e(0x28f));}}),document[_0x3e8868(0x33f)](_0x3e8868(0x1a8),function(_0x291a5e){const _0x5b8ed4=_0x3e8868,_0x2636d4={'ythIe':function(_0x339797,_0x335d07){return _0x339797===_0x335d07;},'reSYQ':_0x5b8ed4(0x190),'PxdkO':'incorrect','RQHQh':_0x5b8ed4(0x2e8),'YEwlJ':function(_0x5b1a55,_0x404a89){return _0x5b1a55!==_0x404a89;},'WLMAU':_0x5b8ed4(0x1e8),'ggHEk':_0x5b8ed4(0x301),'bQMsD':function(_0x1c4ce5,_0x2f949a){return _0x1c4ce5===_0x2f949a;},'gJaAe':'performanceModal','nfEtL':function(_0xdc46cf,_0x433e40){return _0xdc46cf===_0x433e40;},'WIdnW':_0x5b8ed4(0x167),'PebsH':function(_0xf73dc3,_0x2296cc){return _0xf73dc3-_0x2296cc;},'jpniV':function(_0x5495d2,_0x3518c4){return _0x5495d2(_0x3518c4);},'RabBy':_0x5b8ed4(0x21b),'JsVju':function(_0x4a04ad,_0x3afdcb){return _0x4a04ad<_0x3afdcb;},'juRMV':function(_0x393a2e,_0x2efec4){return _0x393a2e===_0x2efec4;},'aQhFD':_0x5b8ed4(0x14b),'ZYREM':function(_0x19858e){return _0x19858e();},'YZqap':_0x5b8ed4(0x259),'kTHiM':function(_0xd3a45a,_0x571b6d){return _0xd3a45a!==_0x571b6d;},'puQiV':'eVeXU','BsKvd':function(_0x13cb81,_0x2ea319){return _0x13cb81===_0x2ea319;},'FjdGy':_0x5b8ed4(0x1b2),'iuBSJ':function(_0x2355a7){return _0x2355a7();},'ZgCYN':_0x5b8ed4(0x36e),'oFCgX':_0x5b8ed4(0xda),'rMfNE':function(_0x253f14,_0x1c36f7){return _0x253f14===_0x1c36f7;},'feiaC':function(_0x1eb1c2,_0x318281){return _0x1eb1c2===_0x318281;}};if(_0x2636d4[_0x5b8ed4(0x12a)](document[_0x5b8ed4(0x2d4)](_0x2636d4['WLMAU'])['style'][_0x5b8ed4(0x302)],_0x2636d4[_0x5b8ed4(0x2ef)]))return;if(_0x2636d4[_0x5b8ed4(0x260)](document[_0x5b8ed4(0x2d4)](_0x2636d4['gJaAe'])[_0x5b8ed4(0x2dc)][_0x5b8ed4(0x2c0)](_0x5b8ed4(0x1ae)),![]))return;if(_0x291a5e['key']>='1'&&_0x291a5e[_0x5b8ed4(0x2f3)]<='4'){if(_0x2636d4[_0x5b8ed4(0x22f)](_0x2636d4['WIdnW'],_0x2636d4[_0x5b8ed4(0x289)])){const _0x54eaeb=_0x2636d4[_0x5b8ed4(0x1b6)](_0x2636d4[_0x5b8ed4(0x156)](parseInt,_0x291a5e[_0x5b8ed4(0x2f3)]),0x1),_0x3e49ee=document['querySelectorAll'](_0x2636d4['RabBy']);if(_0x2636d4[_0x5b8ed4(0xf9)](_0x54eaeb,_0x3e49ee[_0x5b8ed4(0x303)]))_0x2636d4[_0x5b8ed4(0x156)](selectOption,_0x54eaeb);}else{const _0x31f51c=_0x2f9cb2[_0x1310a2];_0x31f51c[_0x5b8ed4(0x285)]!==null&&(_0x2636d4[_0x5b8ed4(0x269)](_0x1f3bd8[_0x5b8ed4(0x1d2)][_0x31f51c[_0x5b8ed4(0x285)]]['id'],_0x27671a['correct_choice_id'])?(_0x29303b++,_0x31f51c[_0x5b8ed4(0x226)]=_0x2636d4['reSYQ']):(_0x42b4a4++,_0x31f51c[_0x5b8ed4(0x226)]=_0x2636d4[_0x5b8ed4(0xdb)]));}}else{if(_0x2636d4[_0x5b8ed4(0x379)](_0x291a5e[_0x5b8ed4(0x2f3)],_0x2636d4[_0x5b8ed4(0x311)]))_0x2636d4[_0x5b8ed4(0x25b)](previousQuestion);else{if(_0x291a5e[_0x5b8ed4(0x2f3)]===_0x2636d4[_0x5b8ed4(0x355)]||_0x291a5e[_0x5b8ed4(0x2f3)]==='\x20'){if(_0x2636d4['kTHiM'](_0x2636d4[_0x5b8ed4(0x1e4)],_0x2636d4[_0x5b8ed4(0x1e4)])){const _0x1382bc=_0x16e487[_0x5b8ed4(0x1c7)](_0x5b8ed4(0x1af));_0x1382bc['textContent']=_0x3b2eca+0x1,_0x1382bc[_0x5b8ed4(0x272)]=_0x2636d4[_0x5b8ed4(0x331)],_0x1382bc[_0x5b8ed4(0x25e)]=()=>_0x57d8a3(_0x4bd2d2),_0x1382bc['id']=_0x5b8ed4(0x19b)+_0x13bff1,_0x1f7efd[_0x5b8ed4(0x277)](_0x1382bc);}else _0x291a5e[_0x5b8ed4(0xcd)](),nextQuestion();}else{if(_0x2636d4[_0x5b8ed4(0x295)](_0x291a5e[_0x5b8ed4(0x2f3)]['toLowerCase'](),'b')&&(currentMode===_0x5b8ed4(0x352)||currentMode===_0x2636d4[_0x5b8ed4(0x1c8)]))_0x2636d4[_0x5b8ed4(0x191)](toggleBookmark);else{if(_0x2636d4[_0x5b8ed4(0x379)](_0x291a5e[_0x5b8ed4(0x2f3)][_0x5b8ed4(0x173)](),'m')&&(currentMode===_0x2636d4[_0x5b8ed4(0xf3)]||_0x2636d4[_0x5b8ed4(0x295)](currentMode,_0x2636d4[_0x5b8ed4(0x177)])))toggleMarkForReview();else _0x2636d4[_0x5b8ed4(0x260)](_0x291a5e[_0x5b8ed4(0x2f3)][_0x5b8ed4(0x173)](),'s')&&(_0x2636d4['rMfNE'](currentMode,_0x2636d4[_0x5b8ed4(0xf3)])||_0x2636d4[_0x5b8ed4(0x1fd)](currentMode,_0x2636d4['oFCgX']))&&_0x2636d4['ZYREM'](submitQuiz);}}}}});</script>

</body></html>